Ashland Inc.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 11:18

Annual Report for Fiscal Year Ending 09-30, 2026 (Form 10-K)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements for the years ended September 30, 2026, 2025 and 2024.

BUSINESS OVERVIEW

Ashland profile

Ashland is a global additives and specialty ingredients company with a conscious and proactive mindset for sustainability. The Company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. With approximately 2,800 employees worldwide, Ashland serves customers in more than 100 countries.

Ashland's sales generated outside of North America were 73%, 73% and 69% for the years ended September 30, 2026, 2025 and 2024, respectively. Sales by region expressed as a percentage of total consolidated sales for the years ended September 30, were as follows:

2026

2025

2024

North America(a)

27

%

27

%

31

%

Europe(a)

36

%

37

%

35

%

Asia Pacific

27

%

26

%

25

%

Latin America & other

10

%

10

%

9

%

100

%

100

%

100

%

(a)
Ashland includes only the U.S. and Canada in its North America designation and includes Europe, the Middle East and Africa in its Europe designation.

Reportable segments

Ashland's reportable segments include Life Sciences, Personal Care, Specialty Additives and Intermediates. Unallocated and other includes corporate governance activities and certain legacy matters. The contribution to sales by each reportable segment expressed as a percentage of total consolidated sales for the years ended September 30, were as follows:

2026

2025

2024

Life Sciences

36

%

35

%

38

%

Personal Care

32

%

32

%

30

%

Specialty Additives

27

%

28

%

27

%

Intermediates

5

%

5

%

5

%

100

%

100

%

100

%

KEY DEVELOPMENTS

Uncertainty related to tariffs and global trade policy changes

Fiscal 2026 saw increased and continuing regulatory activity involving notable changes to U.S. and foreign trade policy, leading to significant uncertainty in the macroeconomic and geopolitical environments. Beginning in fiscal 2025, the U.S. instituted a series of tariffs on imports from China, the EU, India, and other countries which has resulted in the imposition of retaliatory measures against U.S. goods. As a global business, we are exposed

M-1

to risks associated with tariffs and other trade conflicts. Such risks may include, but are not limited to, (i) changes to and strains on the global supply chain and our ability to source materials; (ii) increased sourcing and manufacturing costs; (iii) decreased demand for Ashland's products in affected markets; and (iv) other impacts on Ashland's ability to operate optimally.

The ultimate impact of these recent tariffs and trade disputes on general economic conditions, and on Ashland's business, financial performance, and results of operations, is uncertain and depends on various factors, including the duration of the tariffs and disputes, negotiations between the U.S. and affected countries, whether additional or incremental tariffs are imposed and the responses of other countries or regions, and the potential for trade restriction-related exemptions. Given the dynamic nature of the situation, Ashland continues to monitor tariff developments as well as the broader global trade landscape and is working to mitigate potential impacts on its business.

Uncertainty relating to the ongoing United States, Israel/Iran, Ukraine/Russia and Israel/Hamas conflicts and other political events

Business disruptions, including those related to the ongoing conflicts between the United States, Israel/Iran, Ukraine/Russia, and Israel/Hamas, as well as the recent political events in Venezuela, continue to impact businesses around the globe. While it is impossible to predict the effects of the conflicts, they may include escalating geopolitical tensions (including the imposition of existing and additional sanctions by the U.S. and the EU on Russia), worsening macroeconomic and general business conditions, supply chain interruptions and unfavorable energy markets, and the impact to Ashland could be material. Ashland is closely monitoring these situations and maintains business continuity plans that are intended to continue operations and mitigate the effects of events that could disrupt its business.

Ashland does not have manufacturing operations in Israel, Russia, Ukraine, Venezuela, Iran or Belarus. Ashland sells (or previously sold) additives and specialty ingredients to manufacturers in these countries for their use in pharmaceuticals, personal care, and coatings applications. Sales to Russia and Belarus were previously limited and our products were primarily used in products and applications that are essential to the population's well-being and currently support our customers' humanitarian efforts. We have sales controls in place to ensure that future potential sales into the region are only to support critical pharmaceutical or personal hygiene products which are essential for the general population and in accordance with any applicable sanctions. Sales to Israel, Ukraine, Venezuela, Russia, and Belarus represent less than 1% of total consolidated sales and less than 1% of total consolidated assets (related to accounts receivable). Ashland had no sales activity with Iran.

Other significant items

Restructuring programs

As previously announced, Ashland initiated a $30 million pre-tax restructuring plan to offset the impact from the Nutraceuticals business sale completed in 2024, the Avoca business sale completed in 2025, and other portfolio optimization actions. These actions are substantially complete. Ashland realized approximately $32 million of pre-tax savings under the plan through 2026, of which $12 million and $20 million were realized for the years ended September 30, 2026 and 2025, respectively. See Note D of the Notes to Consolidated Financial Statements for more information.

M-2

Ashland also executed its portfolio optimization actions to further strengthen Ashland's resilience and improve margins and returns. These previously announced actions include initiatives focused on carboxymethylcellulose ("CMC"), methylcellulose ("MC"), the Nutraceuticals business sale and the Avoca business sale (collectively, "Portfolio Optimization"). These actions are substantially complete. Overall, these Portfolio Optimization actions lowered sales and earnings before income taxes, depreciation and amortization ("EBITDA") adjusted for discontinued operations and key items ("Adjusted EBITDA") by $11 million and $1 million for the year ended September 30, 2026 compared to the year ended September 30, 2025, respectively. Operating income (loss) was favorably impacted by $4 million for the year ended September 30, 2026 compared to the year ended September 30, 2025.

Ashland is also advancing a multi-year manufacturing optimization restructuring plan to improve operational cost and strengthen its competitive position. This optimization plan is expected to generate pre-tax savings of $50 million to $55 million with $60 million being achievable as market conditions improve, particularly within China. Ashland has realized cumulative savings of approximately $21 million under the plan, including $16 million in 2026.

The following table summarizes the expense impact of the Portfolio Optimization actions for the years ended September 30:

(In millions)

2026

2025

2024

Accelerated depreciation(a)

$

5

$

41

$

57

Restructuring, separation and other costs(b)

23

22

30

Other plant optimization costs(a)

21

22

10

$

49

$

85

$

97

(a)
Recorded within the cost of sales caption within the Statements of Consolidated Comprehensive Income (Loss).
(b)
Recorded within the selling, general and administrative expense caption within the Statements of Consolidated Comprehensive Income (Loss).

RESULTS OF OPERATIONS - CONSOLIDATED REVIEW

Consolidated review

Overview

Key financial results included the following for the years ended September 30:

2026

2025

(In millions except per share data)

2026

2025

2024

change

change

Net income (loss)

$

4

$

(845

)

$

169

$

849

$

(1,014

)

Diluted earnings per share ("EPS") net income (loss)(a)

0.09

(18.23

)

3.36

18.32

(21.59

)

Income (loss) from continuing operations

25

(822

)

199

847

(1,021

)

Diluted EPS income (loss) from continuing operations(a)

0.55

(17.74

)

3.95

18.29

(21.69

)

Operating income (loss)

105

(775

)

(26

)

880

(749

)

EBITDA(b)

268

(601

)

142

869

(743

)

Adjusted EBITDA(b)

385

401

459

(16

)

(58

)

Adjusted Diluted EPS from Continuing Operations Excluding Intangibles Amortization Expense(b)

3.31

3.38

4.45

(0.07

)

(1.07

)

(a)
As a result of the loss from continuing operations attributable to Ashland for the year ended September 30, 2025, the effect of the share-based awards convertible to common stock would be antidilutive and have been excluded from the diluted EPS calculation.
(b)
These are non-GAAP financial measures. See "Use of Non-GAAP Financial Measures" section below for reconciliations to U.S. GAAP.

M-3

Ashland's net income of $4 million ($0.09 diluted EPS) in 2026, net loss of $845 million (loss of $18.23 diluted EPS) in 2025 and net income of $169 million ($3.36 diluted EPS) in 2024 included losses from discontinued operations of $21 million (loss of $0.46 diluted EPS), $23 million (loss of $0.49 diluted EPS) and $30 million (loss of $0.59 diluted EPS) in 2026, 2025 and 2024, respectively.

Results for Ashland's continuing operations, diluted earnings (loss) per share from continuing operations and operating income (loss) for the years ended September 30, 2026, 2025 and 2024 included certain key items that were excluded to arrive at Adjusted EBITDA and are quantified in the "Use of Non-GAAP Financial Measures" section of this Annual Report on Form 10-K. These pre-tax key items totaled expense of $87 million, $959 million and $227 million in 2026, 2025 and 2024, respectively, impacting continuing operations, including a non-cash goodwill impairment charge of $706 million in 2025 ($375 million for the Life Sciences and $331 million for the Specialty Additives reportable segments, respectively). Continuing operations was also impacted by unfavorable discrete tax items totaling $7 million and $31 million in 2026 and 2025, respectively, and favorable discrete items totaling $234 million in 2024, for various tax specific key items for uncertain tax positions, valuation allowances, restructuring and separation activity and tax reform related activity. The pre-tax key items impacting operating income (loss) totaled expense of $103 million, $982 million, and $273 million in 2026, 2025 and 2024, respectively. Excluding these key items, continuing operations, diluted EPS from continuing operations and operating income (loss) remained relatively flat from 2025 to 2026, primarily driven by higher sales volumes and favorable price/mix offset by unfavorable production costs and higher selling, general and administrative expenses. The decrease in income from continuing operations, diluted EPS from continuing operations and operating income (loss) from 2024 to 2025 was driven by Portfolio Optimization actions, reduced volume, and lower pricing, which was partially offset by lower selling, administrative, research and development costs. In addition, diluted EPS from continuing operations was also impacted by common share reductions from repurchases of Ashland common stock in the amount of zero, $100 million and $380 million in 2026, 2025 and 2024, respectively. The number of weighted-average common shares outstanding was 46 million, 47 million, and 50 million diluted shares at September 30, 2026, 2025 and 2024, respectively, excluding any antidilutive impact.

Ashland's Adjusted EBITDA was $385 million, $401 million, and $459 million for 2026, 2025 and 2024, respectively (see U.S. GAAP reconciliation under "Use of Non-GAAP Financial Measures" below). Adjusted EBITDA decreased from 2025 to 2026 primarily due to unfavorable production costs and higher selling, general and administrative expenses, partially offset by higher sales volumes, price/mix and favorable foreign currency exchange. Adjusted EBITDA decreased from 2024 to 2025 primarily due to Portfolio Optimization actions, reduced volume, and lower pricing, which was partially offset by lower selling, administrative, research and development costs. Adjusted Diluted EPS from Continuing Operations (non-GAAP) Excluding Intangibles Amortization Expense was also impacted by these key factors along with the impact of common share repurchases noted above.

For further information on the items reported above, see the discussion in the comparative Statements of Consolidated Comprehensive Income (Loss) caption review.

M-4

Statements of Consolidated Comprehensive Income (Loss) - caption review

A comparative analysis of the Statements of Consolidated Comprehensive Income (Loss) by caption is provided as follows for the years ended September 30:

2026

2025

(In millions)

2026

2025

2024

change

change

Sales

$

1,863

$

1,824

$

2,113

$

39

$

(289

)

The following table provides a reconciliation of the change in sales between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Sales change

Volume

$

29

$

(98

)

Foreign currency exchange

25

8

Price/mix

(4

)

(46

)

Divestitures

(11

)

(153

)

Change in sales

$

39

$

(289

)

Sales for 2026 increased $39 million, or 2%, compared to 2025. The increase was driven by higher volume, and favorable foreign currency exchange, which was partially offset by unfavorable price/mix and the impact of the Avoca business sale. Portfolio Optimization actions had a negative $11 million impact on sales in the current year compared to the prior year, primarily within divestitures and volume caption changes.

Sales for 2025 decreased $289 million, or 14%, compared to 2024. The decrease was driven by the unfavorable impact of divestitures, lower volume, and unfavorable pricing, which was partially offset by favorable foreign currency exchange. Portfolio Optimization actions had a $208 million impact on sales in 2025 compared to 2024, primarily within divestitures and volume caption changes.

2026

2025

(In millions)

2026

2025

2024

change

change

Cost of sales

$

1,262

$

1,275

$

1,495

$

(13

)

$

(220

)

Gross profit as a percent of sales

32.3

%

30.1

%

29.2

%

Fluctuations in cost of sales were impacted by product line and plant optimization costs in 2026, 2025 and 2024. In addition, divestitures and other certain charges incurred relating to Portfolio Optimization actions contributed to a significant impact in 2025.

The following table provides a reconciliation of the changes in cost of sales between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Cost of sales change

Price/mix

$

(26

)

$

16

Divestiture

(11

)

(123

)

Operating costs

(7

)

(37

)

Volume

14

(81

)

Foreign currency exchange

17

5

Change in cost of sales

$

(13

)

$

(220

)

M-5

Cost of sales for 2026 decreased $13 million compared to 2025. The decrease was primarily driven by favorable price/mix, the favorable impact of divestitures and lower operating costs, which includes plant optimization costs, partially offset by higher volumes and unfavorable foreign exchange currency. The current year operating costs were affected by $4 million of accelerated depreciation for product line optimization activities at manufacturing facilities within the Life Sciences, Personal Care and Specialty Additives reportable segments and $21 million of other plant optimization costs while the prior year period included $41 million of accelerated depreciation for product line optimization activities at manufacturing facilities within the Life Sciences, Personal Care and Specialty Additives reportable segments, and $22 million of other plant optimization costs. Gross profit as a percentage of sales increased 2.2 percentage points as a result of the sales and cost of sales factors noted above.

Cost of sales for 2025 decreased $220 million compared to 2024. The decrease was primarily driven by the favorable impact of divestitures, lower sales volume, and lower operating costs, partially offset by unfavorable pricing and unfavorable foreign exchange currency. Fiscal 2025 operating costs were affected by $41 million of accelerated depreciation for product line optimization activities at manufacturing facilities within the Life Sciences, Personal Care and Specialty Additives reportable segments and $22 million of other plant optimization costs while fiscal 2024 included $57 million of accelerated depreciation for product line optimization activities at two Specialty Additives manufacturing plants and one Personal Care manufacturing plant, and $10 million of other plant optimization costs. Gross profit as a percentage of sales increased 0.9 percentage points as a result of the sales and cost of sales factors noted above.

2026

2025

(In millions)

2026

2025

2024

change

change

Selling, general and administrative expense

$

377

$

344

$

404

$

33

$

(60

)

As a percent of sales

20.2

%

18.9

%

19.1

%

Selling, general and administrative expense for 2026 increased $33 million compared to 2025, while expenses as a percent of sales increased 1.3 percentage points. Key drivers of the fluctuation in selling, general and administrative expense compared to 2025 were:

•
Expense of $23 million and $22 million composed of key items for severance, lease abandonment and other restructuring costs during 2026 and 2025, respectively (see Note D of the Notes to Consolidated Financial Statements for more information);
•
$18 million capital projects impairment charge in 2026 (see Note F of the Notes to Consolidated Financial Statements for more information);
•
$33 million and $34 million in net environmental-related expenses during 2026 and 2025, respectively (see Note M of the Notes to Consolidated Financial Statements for more information);
•
$8 million and $3 million benefits related to domestic tax credits in 2026 and 2025; and
•
Increases associated with the following:
o
Unfavorable foreign currency exchange of $1 million;
o
Higher variable and stock-based compensation expense; and
o
Higher bad debt expense and lower transition services income.

M-6

Selling, general and administrative expense for 2025 decreased $60 million compared to 2024, while expenses as a percent of sales decreased 0.2 percentage points. Key drivers of the fluctuation in selling, general and administrative expense compared to 2024 were:

•
Expense of $22 million and $30 million composed of key items for severance, lease abandonment and other restructuring costs during 2025 and 2024, respectively (see Note D of the Notes to Consolidated Financial Statements for more information);
•
$34 million and $45 million in net environmental-related expenses during 2025 and 2024, respectively (see Note M of the Notes to Consolidated Financial Statements for more information);
•
$11 million capital project impairment charge in 2024;
•
A $5 million charge associated with the impact of a currency devaluation in Argentina during 2024;
•
A $4 million legal settlement during 2024;
•
A $3 million benefit related to domestic tax credits in 2025; and
•
Decreases associated with the following:
o
Lower variable compensation and stock based compensation expense;
o
The favorable impact of divestitures in 2025;
o
The realized cost reductions associated with 2025 restructuring actions; and
o
Favorable foreign currency exchange of $2 million.

2026

2025

(In millions)

2026

2025

2024

change

change

Research and development expense

$

55

$

54

$

55

$

1

$

(1

)

Research and development expense increased $1 million in 2026 compared to 2025 primarily due to higher compensation costs. In 2025, the $1 million decrease compared to 2024 was primarily due to lower compensation costs.

2026

2025

(In millions)

2026

2025

2024

change

change

Intangibles amortization expense

$

60

$

63

$

76

$

(3

)

$

(13

)

Intangibles amortization expense decreased $3 million in 2026 compared to 2025 primarily due to the impact of fully amortized intangibles. Intangibles amortization expense decreased $13 million in 2025 compared to 2024 primarily due to the impact of fully amortized intangibles and the impact of the Avoca business divested during 2025.

2026

2025

(In millions)

2026

2025

2024

change

change

Equity and other income

$

4

$

4

$

6

$

-

$

(2

)

Equity and other income remained consistent in 2026 compared to 2025. Equity and other income decreased in 2025 compared to 2024 primarily related to lower China financial cash subsidies.

2026

2025

(In millions)

2026

2025

2024

change

change

Goodwill impairment

$

-

$

706

$

-

$

(706

)

$

706

M-7

Ashland recorded a $706 million goodwill impairment charge in 2025. See Note G of the Notes to Consolidated Financial Statements for more information.

2026

2025

(In millions)

2026

2025

2024

change

change

Loss on divestitures, net

$

(8

)

$

(161

)

$

(115

)

$

153

$

(46

)

Loss on divestitures, net during 2026 primarily relates to a pre-tax loss related to the recognition of an Argentina foreign currency cumulative translation adjustment of $13 million due to the liquidation of Ashland's Argentina subsidiary, partially offset by sales activity and a pre-tax gain on sale of excess corporate real estate. See Note B of the Notes to Consolidated Financial Statements for more information.

Loss on divestitures, net during 2025 primarily relates to a net $175 million impairment charge and sale of the Avoca business. In addition, Ashland recorded a pre-tax gain on sale of excess corporate real estate of $14 million during 2025. See Note B of the Notes to Consolidated Financial Statements for more information.

Loss on divestitures, net during 2024 primarily relates to $107 million impairment charge and loss on sale associated with the divestiture of the Nutraceuticals business. In addition, a $7 million reserve for foreign value added taxes ("VAT") was also recorded in 2024 associated with the divested Nutraceuticals business. See Note B of the Notes to Consolidated Financial Statements for more information.

2026

2025

(In millions)

2026

2025

2024

change

change

Net interest and other expense (income)

Interest expense

$

61

$

61

$

53

$

-

$

8

Interest income

(6

)

(5

)

(10

)

(1

)

5

Loss on the accounts receivable sale programs

3

8

6

(5

)

2

Investment securities income

(22

)

(33

)

(75

)

11

42

Other financing costs

4

2

2

2

-

$

40

$

33

$

(24

)

$

7

$

57

Net interest and other expense (income) increased by $7 million during 2026 compared to 2025 primarily due to lower investment securities income. Interest expense and interest income are generally consistent between 2026 and 2025. Restricted investments gains of $22 million and $33 million included realized gains of $9 million compared to $20 million for 2026 and 2025, respectively. See Note E of the Notes to Consolidated Financial Statements for more information on the restricted investments.

Net interest and other expense (income) increased by $57 million in 2025 compared to 2024 primarily due to lower investment securities income. Interest expense increased primarily related to lower capitalized interest on capital projects in 2025 while interest income decreased primarily due to the decrease in cash equivalents during 2025 compared to 2024. Restricted investments gains of $33 million and $75 million included realized gains of $20 million compared to $60 million for 2025 and 2024, respectively. See Note E of the Notes to Consolidated Financial Statements for more information on the restricted investments.

2026

2025

(In millions)

2026

2025

2024

change

change

Other net periodic benefit (income) loss

$

(4

)

$

1

$

22

$

(5

)

$

(21

)

M-8

Other net periodic benefit income during 2026 primarily included expected return on plan assets of $10 million, a $5 million gain on pension postretirement plan remeasurements and a $2 million settlement gain offset by interest cost of $13 million.

Other net periodic benefit expense during 2025 primarily included interest cost of $14 million offset by expected return on plan assets of $10 million and a $3 million gain on pension postretirement plan remeasurements.

Other net periodic benefit expense during 2024 primarily included interest cost of $16 million and a $14 million loss on pension postretirement plan remeasurements offset by expected return on plan assets of $8 million.

2026

2025

(In millions)

2026

2025

2024

change

change

Income tax expense (benefit)

$

44

$

13

$

(223

)

$

31

$

236

Effective tax rate

64

%

(2

)%

929

%

The 2026 effective tax rate was impacted by jurisdictional income mix, as well as unfavorable discrete items of $7 million primarily related to changes in valuation allowances, equity compensation adjustments and uncertain tax positions.

The 2025 effective tax rate was impacted by jurisdictional income mix, nondeductible goodwill impairment of $706 million, as well as unfavorable discrete items of $36 million primarily related to changes in state and foreign tax activity and uncertain tax positions.

The 2024 effective tax rate was impacted by jurisdictional income mix, as well as favorable discrete items of $231 million primarily related to changes in foreign tax activity and the tax impact of the Nutraceuticals business divestiture.

Adjusted income tax expense

Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income (loss) and/or operating income (loss) which Ashland believes do not accurately reflect Ashland's underlying business performance and trends. Tax specific key items are defined as the financial effects from tax specific financial transactions, tax law changes or other matters that fall within the definition of key items as previously described. The Effective Tax Rate, Excluding Key Items, which is a non-GAAP measure, has been prepared to illustrate the ongoing tax effects of Ashland's operations. Management believes investors and analysts use this financial measure in assessing Ashland's business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland's ongoing business performance and enhancing their ability to compare period-to-period financial results.

M-9

The effective tax rates during 2026, 2025 and 2024 were significantly impacted by the following tax specific key items:

•
Uncertain tax position - Includes the impact from the settlement of uncertain tax positions with various tax authorities;
•
Valuation allowances - Includes the impact of certain foreign tax credit valuation allowances;
•
Restructuring and separation activity - Includes the tax impact of the Nutraceuticals business divestiture and company-wide restructuring activities; and
•
Other and tax reform related activity - Includes miscellaneous state and foreign statute adjustments.

The following table is a calculation of the effective tax rate, excluding the impact of these key items for the years ended September 30:

(In millions)

2026

2025

2024

Income (loss) from continuing operations before income taxes

$

69

$

(809

)

$

(24

)

Key items (pre-tax)(a)

87

959

227

Adjusted income from continuing operations before income taxes

$

156

$

150

$

203

Income tax expense (benefit)

44

13

(223

)

Income tax rate adjustments:

Tax effect of key items(b)

14

62

31

Tax specific key items:(c)

Uncertain tax positions

-

-

(9

)

Valuation allowance

(7

)

(9

)

(5

)

Restructuring and separation activity

-

-

115

Other and tax reform related activity

-

(22

)

133

Total income tax rate adjustments

7

31

265

Adjusted income tax expense

$

51

$

44

$

42

Effective tax rate

64

%

(2

)%

929

%

Effective Tax Rate, Excluding Key Items (Non-GAAP)(d)

32

%

29

%

20

%

(a)
See Adjusted EBITDA reconciliation table disclosed below in this Managements Discussion and Analysis of Financial Condition and Results of Operation for a summary of the key items, before tax.
(b)
The tax rate specific to the jurisdiction in which the key item originates is used to calculate the tax effect of key items.
(c)
For additional information on the effect that these tax specific key items had on EPS, see the Adjusted Diluted EPS table disclosed below in this Management Discussion and Analysis of Financial Condition and Results of Operation.
(d)
Due to rounding conventions, the effective tax rate presented may not recalculate precisely based on the numbers disclosed within this table.

The following table provides a reconciliation of tax specific key items within the statutory federal income tax with the provision for income taxes summary disclosed in Note K of the Notes to Consolidated Financial Statements for the years ended September 30:

(In millions)

2026

2025

2024

Tax effect of key items computed at applicable statutory rate(a)

$

14

$

62

$

31

Uncertain tax positions

-

-

(9

)

Valuation allowance changes

(7

)

(9

)

(5

)

Basis difference on stock sale

-

-

115

Tax law changes

-

-

49

Non US restructuring

-

(10

)

84

Deemed inclusions, foreign dividends and other restructuring

-

(12

)

-

$

7

$

31

$

265

M-10

(a)
The tax rate specific to the jurisdiction in which the key item originates is used to calculate the tax effect of key items.

A comparative analysis of the components of loss from discontinued operations, net of income taxes is provided below for the years ended September 30:

2026

2025

(In millions)

2026

2025

2024

change

change

Loss from discontinued operations, net of income taxes

Performance Adhesives

$

3

$

(2

)

$

(2

)

$

5

$

-

Valvoline

-

2

2

(2

)

-

Composites/Marl Facility

-

-

(2

)

-

2

Water Technologies

-

-

(4

)

-

4

Distribution

(4

)

(10

)

(6

)

6

(4

)

Asbestos-related litigation

(20

)

(13

)

(18

)

(7

)

5

$

(21

)

$

(23

)

$

(30

)

$

2

$

7

The activity for Water Technologies, Valvoline, Composites/Marl Facility, Performance Adhesives and Distribution during 2026, 2025 and 2024, represents subsequent adjustments that were made in conjunction with the environmental remediation and tax related reserves. Asbestos-related activity during 2026, 2025 and 2024 included after-tax net expense adjustments to the asbestos litigation reserves and receivables including the adjustments for the annual update for each of these years. See Note C of the Notes to Consolidated Financial Statements for more information related to discontinued operations.

Other comprehensive income

A comparative analysis of the components of other comprehensive income is provided below for the years ended September 30:

2026

2025

(In millions)

2026

2025

2024

change

change

Other comprehensive income, net of tax

Unrealized translation gain

$

1

$

45

$

54

$

(44

)

$

(9

)

Unrealized gain on commodity hedges

2

2

1

-

1

$

3

$

47

$

55

$

(44

)

$

(8

)

Total other comprehensive income, net of tax, decreased $44 million in 2026 compared to 2025, as a result of the following component:

•
In 2026, the change in unrealized gain from foreign currency translation adjustments resulted in a gain of $1 million, compared to a gain of $45 million during 2025. The fluctuations in unrealized translation gains and losses were primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.

Total other comprehensive income, net of tax, decreased $8 million in 2025 compared to 2024 as a result of the following components:

•
In 2025, the change in unrealized gain from foreign currency translation adjustments resulted in a gain of $45 million, compared to a gain of $54 million during 2024. The fluctuations in unrealized translation gains

M-11

and losses were primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars; and
•
In 2025, a $2 million unrealized gain on commodity hedges was recorded compared to $1 million during 2024.

Use of Non-GAAP Financial Measures

Ashland has included within this document the following non-GAAP financial measures, on both a consolidated and reportable segment basis, which are not defined within U.S. GAAP and do not purport to be alternatives to net income (loss) or cash flows from operating activities as a measure of operating performance or cash flows:

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin

EBITDA is defined as net income (loss), plus income tax expense (benefit), net interest and other expense (income), and depreciation and amortization. Adjusted EBITDA is EBITDA adjusted for discontinued operations and key items (including remeasurement gains and losses related to pension and other postretirement plans). Adjusted EBITDA margin is Adjusted EBITDA divided by sales.

Management believes the use of EBITDA and Adjusted EBITDA measures on a consolidated and reportable segment basis assists investors in understanding the ongoing operating performance by presenting comparable financial results between periods. Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA and Adjusted EBITDA provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income (loss) and operating income (loss). The adjustments Ashland makes to derive the non-GAAP financial measures of EBITDA and Adjusted EBITDA exclude items which may cause short-term fluctuations in net income (loss) and operating income (loss) and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA and Adjusted EBITDA provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its segments and provide continuity to investors for comparability purposes.

Adjusted Diluted Earnings Per Share ("EPS")

Adjusted Diluted EPS is defined as income (loss) from continuing operations, adjusted for key items, net of tax, divided by the average outstanding diluted shares for the applicable period. The Adjusted Diluted EPS metric enables Ashland to demonstrate what effect key items have on EPS by taking income (loss) from continuing operations, adjusted for key items after tax that have been identified in the Adjusted EBITDA table, and dividing by the average outstanding diluted shares for the applicable period. Ashland's management believes this presentation is helpful to illustrate how the key items have impacted this metric during the applicable period.

M-12

Adjusted Diluted Earnings Per Share ("EPS") Excluding Intangibles Amortization Expense

The Adjusted Diluted EPS Excluding Intangible Amortization Expense is Adjusted Diluted EPS adjusted for intangibles amortization expense net of tax, divided by the average outstanding diluted shares for the applicable period. The Adjusted Diluted EPS, Excluding Intangibles Amortization Expense metric enables Ashland to demonstrate the impact of non-cash intangibles amortization expense on EPS, in addition to the key items previously mentioned. Ashland's management believes this presentation is helpful to illustrate how previous acquisitions impact applicable period results.

Free Cash Flow, Ongoing Free Cash Flow and Ongoing Free Cash Flow Conversion

Free Cash Flow is defined as operating cash flows less capital expenditures while Ongoing Free Cash Flow is operating cash flows less capital expenditures and certain other adjustments as applicable. Ongoing Free Cash Flow Conversion is Ongoing Free Cash Flow divided by Adjusted EBITDA. These Free Cash Flow metrics enable Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, Free Cash Flow and Ongoing Free Cash Flow includes the impact of capital expenditures from continuing operations and other significant items impacting cash flow, providing a more complete picture of current and future cash generation. Free Cash Flow, Ongoing Free Cash Flow, and Free Cash Flow Conversion are non-GAAP liquidity measures that Ashland believes provide useful information to management and investors about Ashland's ability to convert Adjusted EBITDA to Ongoing Free Cash Flow. These liquidity measures are used regularly by Ashland's stakeholders and industry peers to measure the efficiency at providing cash from regular business activity. Free Cash Flow, Ongoing Free Cash Flow, and Ongoing Free Cash Flow Conversion have certain limitations, including that they do not reflect adjustments for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Other disclosures on non-GAAP financial measures

Although Ashland may provide forward-looking guidance for Adjusted EBITDA, Adjusted Diluted EPS and Ongoing Free Cash Flow, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items that affect these metrics such as domestic and international economic, political, legislative, regulatory and legal actions. In addition, certain economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies and changes in the prices of certain key raw materials, can have a significant effect on operations and are difficult to predict with certainty.

These non-GAAP financial measures should be considered supplemental in nature and should not be construed as more significant than comparable measures defined by U.S. GAAP. Limitations associated with the use of these non-GAAP financial measures include that these measures do not present all of the amounts associated with our results as determined in accordance with U.S. GAAP. The non-GAAP financial measures provided are used by Ashland management and may not be determined in a manner consistent with the methodologies used by other companies. EBITDA and Adjusted EBITDA provide a supplemental presentation of

M-13

Ashland's operating performance on a consolidated and reportable segment basis. Adjusted EBITDA generally includes adjustments for items that impact comparability between periods. In addition, certain financial covenants related to Ashland's 2026 Credit Agreement are based on similar non-GAAP financial measures and are defined further in the sections that reference this metric.

In accordance with U.S. GAAP, Ashland recognizes actuarial gains and losses for defined benefit pension and other postretirement benefit plans annually in the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement during a fiscal year. Actuarial gains and losses occur when actual experience differs from the estimates used to allocate the change in value of pension and other postretirement benefit plans to expense throughout the year or when assumptions change, as they may each year. Significant factors that can contribute to the recognition of actuarial gains and losses include changes in discount rates used to remeasure pension and other postretirement obligations on an annual basis or upon a qualifying remeasurement, differences between actual and expected returns on plan assets and other changes in actuarial assumptions, for example, the life expectancy of plan participants. Management believes Adjusted EBITDA, which includes the expected return on pension plan assets yet excludes both the actual return on pension plan assets and the impact of actuarial gains and losses, provides investors with a meaningful supplemental presentation of Ashland's operating performance (see the Adjusted EBITDA reconciliation table for additional details on exact amounts included within this non-GAAP measure related to pension and other postretirement plans). Management believes these actuarial gains and losses are primarily financing activities that are more reflective of changes in current conditions in global financial markets (and in particular interest rates) that are not directly related to the underlying business. For further information on the actuarial assumptions and plan assets referenced above, see Note L of the Notes to Consolidated Financial Statements.

EBITDA and Adjusted EBITDA

EBITDA totaled $268 million, ($601) million and $142 million for 2026, 2025 and 2024, respectively. EBITDA and Adjusted EBITDA results in the following table have been prepared to illustrate the ongoing effects of Ashland's operations, which exclude certain key items previously described. Management believes the use of such non-GAAP financial measures on a consolidated and reportable segment basis assists investors in understanding the ongoing operating performance by presenting the financial results between periods on a more comparable basis.

These operating key items for the applicable periods are summarized as follows:

•
Environmental remediation reserves adjustments - Ashland is subject to various federal, state and local environmental laws and regulations that require environmental assessment or remediation efforts (collectively environmental remediation) at multiple locations. As a result of these activities, Ashland recorded adjustments during each year to its environmental remediation reserves and receivables primarily related to previously divested businesses or non-operational sites. See Note M of the Notes to Consolidated Financial Statements for more information;
•
Restructuring, separation and other costs - Ashland periodically implements company-wide and targeted cost reduction programs related to acquisitions, divestitures and other cost reduction programs in order to enhance profitability through streamlined operations and an improved overall cost structure. Ashland often incurs severance, facility and integration costs associated with these programs.

M-14

See Note D of the Notes to Consolidated Financial Statements for further information on the restructuring activities;
•
Other plant optimization costs - During 2026, 2025 and 2024, Ashland incurred inventory adjustment and production costs associated with product line optimization actions;
•
Asset impairments - Ashland recognized non-cash impairment charges to certain assets during 2026 and 2024. See Note F of the Notes to Consolidated Financial Statements for more information;
•
Argentina liquidation cumulative translation adjustment - Ashland recorded a pre-tax loss of $13 million related to the recognition of an Argentina foreign currency cumulative translation adjustment due to the liquidation of Ashland's Argentina subsidiary within the loss on divestitures, net caption of the Statement of Consolidated Comprehensive Income (Loss);
•
Accelerated depreciation - As a result of product line optimization activities at manufacturing facilities within the Life Sciences, Specialty Additives and Personal Care reportable segments and Unallocated and other, Ashland recorded accelerated depreciation due to changes in the expected useful life of certain property, plant and equipment during 2026, 2025 and 2024. See Note D of the Notes to Consolidated Financial Statements for more information;
•
Goodwill impairment - Ashland recorded a non-cash goodwill impairment charge of $706 million within the goodwill impairment caption of the Statement of Consolidated Comprehensive Income (Loss) in 2025. See Note G of the Notes to Consolidated Financial Statements for more information;
•
Avoca business impairment and sale - During 2025, Ashland sold substantially all of the net assets of its Avoca business. As a result, Ashland recorded an impairment charge and gain on sale within the loss on divestitures, net caption of the Statement of Consolidated Comprehensive Income (Loss) in 2025. See Note B of the Notes to Consolidated Financial Statements for more information;
•
Nutraceutical business impairment and sale - During 2024, Ashland sold substantially all of the net assets of its Nutraceuticals business. As a result, Ashland recorded an impairment charge and loss on sale within the loss on divestitures, net caption of the Statements of Consolidated Comprehensive Income (Loss) in 2024 and post-closing adjustments in 2025. See Note B of the Notes to Consolidated Financial Statements for more information;
•
Held for sale depreciation and amortization - Represents the depreciation and amortization for the Avoca business during 2025 and the Nutraceuticals business during 2024. See Note B of the Notes to Consolidated Financial Statements for more information;
•
Nutraceuticals VAT reserve - During 2024, Ashland incurred a VAT reserve associated with the sale of the Nutraceuticals business;
•
Argentina foreign currency devaluation - Following the enactment by the Argentina government of a 50% peso devaluation against the dollar, Ashland recorded a currency devaluation charge within the selling, general and administrative expense caption of the Statement of Consolidated Comprehensive Income (Loss) during 2024;

M-15

•
Legal settlement - During 2024, Ashland incurred $4 million in costs associated with a legal settlement;
•
Income on divestitures, net - During 2026 and 2025, Ashland recorded income of $2 million and $14 million, respectively, relating to the pre-tax gains in connection with the sale of excess corporate properties. See Note B of the Notes to Consolidated Financial Statements for more information; and
•
Tax credit - During 2026 and 2025, Ashland recorded $8 million and $3 million, respectively, of benefits related to domestic tax credits within Unallocated and other.

Non-operating key items affecting EBITDA

During the current and prior years, there were certain key items that were not included in operating income (loss) but were excluded to arrive at Adjusted EBITDA. These non-operating key items for the applicable periods are summarized as follows:

•
(Gain) loss on pension and other postretirement plan remeasurements - Ashland recognized actuarial gains and losses for defined benefit pension and other postretirement benefit plans annually in the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement during a fiscal year. Ashland also recognized a settlement gain and a gain for pension plan remeasurement from a buy-out transaction affecting certain defined benefit pension plans in 2026 and a curtailment loss for pension plan remeasurement for a defined benefit pension plan in 2025. See Note L of the Notes to Consolidated Financial Statements for more information.

M-16

Reconciliation of Non-GAAP Financial Measures

(In millions)

2026

2025

2024

Net income (loss)

$

4

$

(845

)

$

169

Income tax expense (benefit)

44

13

(223

)

Net interest and other expense (income)

40

33

(24

)

Depreciation and amortization(a)

180

198

220

EBITDA

268

(601

)

142

Loss from discontinued operations, net of income taxes

21

23

30

Key items included in EBITDA:

Environmental remediation reserves adjustments

33

34

45

Restructuring, separation and other costs

23

22

30

Other plant optimization costs

21

22

10

Asset impairments

18

-

11

Argentina liquidation cumulative translation adjustment

13

-

-

Accelerated depreciation

5

41

57

Goodwill impairment

-

706

-

Avoca business impairment and sale

-

175

-

Nutraceutical business impairment and sale

-

1

107

Held for sale depreciation and amortization

-

(2

)

(3

)

Nutraceuticals VAT reserve

-

-

7

Argentina currency devaluation impact

-

-

5

Legal settlement

-

-

4

Income on divestitures, net

(2

)

(14

)

-

Tax credit

(8

)

(3

)

-

(Gain) loss on pension and other postretirement plan remeasurements(b)

(7

)

(3

)

14

Total key items included in EBITDA

96

979

287

Adjusted EBITDA(b)

$

385

$

401

$

459

Total key items included in EBITDA

$

96

$

979

$

287

Unrealized gains on securities

(9

)

(20

)

(60

)

Total key items, before tax

$

87

$

959

$

227

(a)
Depreciation and amortization excludes accelerated depreciation of $21 million for Life Sciences for the year ended September 30, 2025, $1 million, $1 million and $2 million for Personal Care for the years ended September 30, 2026, 2025 and 2024, respectively, $3 million, $19 million and $55 million for Specialty Additives for the years ended September 30, 2026, 2025 and 2024, respectively, and $1 million for Unallocated and other for the year ended September 30, 2026, which is included as a key item within this table as a component of Adjusted EBITDA. Depreciation and amortization includes $2 million for Personal Care associated with the Avoca business for the year ended September 30, 2025 and $3 million for Life Sciences associated with the Nutraceuticals business for the year ended September 30, 2024, which is included as a key item within this table as a component of Adjusted EBITDA.
(b)
Includes $7 million, $7 million, and $12 million of net periodic loss recognized ratably through the years ended September 30, 2026, 2025 and 2024, respectively. These expenses are composed of service cost, interest cost, expected return on plan assets, and amortization of prior service credit and are disclosed in further detail in Note L of the Notes to Consolidated Financial Statements.

Diluted EPS and Adjusted Diluted EPS

The following table reflects the U.S. GAAP calculation for the income (loss) from continuing operations adjusted for the cumulative diluted EPS effect for key items after tax that have been identified in the Adjusted EBITDA table in the previous section. Key items are defined as the financial effects from significant transactions that may have caused short-term fluctuations in net income (loss) and/or operating income (loss) which Ashland believes do not accurately reflect Ashland's underlying business performance and trends. The Adjusted Diluted EPS for the income (loss) from continuing operations and Adjusted Diluted EPS from Continuing Operations

M-17

Excluding Intangibles Amortization Expense in the following table have been prepared to illustrate these ongoing effects on Ashland's operations. Management believes investors and analysts use this financial measure in assessing Ashland's business performance and that presenting this non-GAAP measure on a consolidated basis assists investors in better understanding Ashland's ongoing business performance and enhancing their ability to compare period-to-period financial results.

In addition to the operating key items previously described, additional non-operating key items for the applicable periods are summarized as follows:

•
Unrealized gains on securities - represents gains recognized on restricted investments related to the Asbestos trust and Environmental trust for each period. See Note E of the Notes to Consolidated Financial Statements for more information;
•
Uncertain tax positions - represents the impact from the settlement of uncertain tax positions with various tax authorities for fiscal 2024;
•
Valuation allowance - represents the impact of certain foreign tax credit valuation allowances;
•
Restructuring and separation activity - represents the tax impact of the held for sale classification for the Nutraceuticals business; and
•
Other and tax reform related activity - represents tax specific key items associated with foreign tax related activity for fiscal 2025 and 2024.

M-18

Reconciliation of Non-GAAP Financial Measures

2026

2025

2024

Diluted EPS from continuing operations (as reported)

$

0.55

$

(17.74

)

$

3.95

Key items, before tax:

Environmental remediation reserves adjustments

0.72

0.76

0.90

Restructuring, separation and other costs

0.50

0.48

0.60

Other plant optimization costs

0.46

0.48

0.20

Asset impairments

0.38

-

0.22

Argentina liquidation cumulative translation adjustment

0.28

-

-

Accelerated depreciation

0.10

0.89

1.14

Goodwill impairment

-

15.22

-

Avoca business impairment and sale

-

3.75

-

Nutraceutical business impairment and sale

-

0.02

2.14

Held for sale depreciation and amortization

-

(0.04

)

(0.06

)

Nutraceuticals VAT reserve

-

-

0.14

Argentina currency devaluation impact

-

-

0.10

Legal settlement

-

-

0.08

Income on divestitures, net

(0.04

)

(0.30

)

-

Tax credit

(0.17

)

(0.07

)

-

(Gain) loss on pension and other postretirement plan remeasurements

(0.16

)

(0.07

)

0.29

Unrealized gains on securities

(0.19

)

(0.42

)

(1.20

)

Key items, before tax

1.88

20.70

4.55

Tax effect of key items(a)

(0.31

)

(1.37

)

(0.62

)

Key items, after tax

1.57

19.33

3.93

Tax specific key items:

Uncertain tax positions

-

-

0.18

Valuation allowance

0.15

0.21

0.10

Restructuring and separation activity

-

-

(2.30

)

Other tax reform related activity

-

0.48

(2.66

)

Tax specific key items(b)

0.15

0.69

(4.68

)

Total key items

1.72

20.02

(0.75

)

Adjusted Diluted EPS from Continuing Operations (non-GAAP)

$

2.27

$

2.28

$

3.20

Intangibles amortization expense adjustment (net of tax)(c)

1.04

1.10

1.25

Adjusted Diluted EPS from Continuing Operations (non-GAAP) Excluding Intangibles Amortization Expense

$

3.31

$

3.38

$

4.45

(a)
Represents the diluted EPS impact from the tax effect of the key items that are previously identified above.
(b)
Represents the diluted EPS impact from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. For additional explanation of these tax specific key items, see the income tax expense (benefit) discussion within the following caption review section.
(c)
Intangibles amortization expense adjustment (net of tax) tax rates were 20% for 2026, 2025 and 2024.

M-19

RESULTS OF OPERATIONS - REPORTABLE SEGMENT REVIEW

Ashland's reportable segments include Life Sciences, Personal Care, Specialty Additives, and Intermediates. Unallocated and Other includes corporate governance activities and certain legacy matters.

Results of Ashland's reportable segments are presented based on its management and internal accounting structure. The structure is specific to Ashland; therefore, the financial results of Ashland's reportable segments are not necessarily comparable with similar information for other companies. Ashland allocates all significant costs to its reportable segments except for certain significant company-wide restructuring activities, certain corporate governance costs and other costs or activities that relate to former businesses that Ashland no longer operates. The service cost component of pension and other postretirement benefits costs is allocated to each reportable segment on a ratable basis; while the remaining components of pension and other postretirement benefits costs are recorded within the other net periodic benefit (income) loss caption on the Statements of Consolidated Comprehensive Income (Loss). Ashland refines its expense allocation methodologies to the reportable segments from time to time as more refined information becomes available and the industry or market changes. Significant revisions to Ashland's methodologies are adjusted for all reportable segments on a retrospective basis. There were no material changes in methodology for the years ended September 30, 2026, 2025 or 2024.

The following table shows sales, operating income (loss), depreciation expense, amortization expense and EBITDA by reportable segment for the years ended September 30:

M-20

2026

2025

(In millions)

2026

2025

2024

change

change

Sales

Life Sciences

$

671

$

641

$

810

$

30

$

(169

)

Personal Care

592

577

634

15

(57

)

Specialty Additives

504

511

572

(7

)

(61

)

Intermediates

135

137

144

(2

)

(7

)

Intersegment sales(a)

(39

)

(42

)

(47

)

3

5

$

1,863

$

1,824

$

2,113

$

39

$

(289

)

Operating income (loss)

Life Sciences(b)

$

131

$

(262

)

$

168

$

393

$

(430

)

Personal Care(c)

101

90

73

11

17

Specialty Additives(d)

(12

)

(338

)

(32

)

326

(306

)

Intermediates

11

8

29

3

(21

)

Unallocated and other(e)

(126

)

(273

)

(264

)

147

(9

)

$

105

$

(775

)

$

(26

)

$

880

$

(749

)

Depreciation expense

Life Sciences(f)

$

38

$

57

$

38

$

(19

)

$

19

Personal Care(g)

28

30

36

(2

)

(6

)

Specialty Additives(h)

54

75

111

(21

)

(36

)

Intermediates

4

12

13

(8

)

(1

)

Unallocated and other(i)

1

-

-

1

-

$

125

$

174

$

198

$

(49

)

$

(24

)

Intangibles amortization expense

Life Sciences

$

18

$

18

$

23

$

-

$

(5

)

Personal Care

32

35

43

(3

)

(8

)

Specialty Additives

9

9

10

-

(1

)

Intermediates

1

1

-

-

1

Unallocated and other

-

-

-

-

-

$

60

$

63

$

76

$

(3

)

$

(13

)

EBITDA(j)

Life Sciences

$

187

$

(187

)

$

229

$

374

$

(416

)

Personal Care

161

155

152

6

3

Specialty Additives

51

(254

)

89

305

(343

)

Intermediates

16

21

42

(5

)

(21

)

Unallocated and other

(125

)

(273

)

(264

)

148

(9

)

$

290

$

(538

)

$

248

$

828

$

(786

)

(a)
Intersegment sales from Intermediates are accounted for at prices that approximate market value. All other intersegment sales are accounted for at cost.
(b)
Includes a $16 million capital projects impairment charge in 2026 and a goodwill impairment of $375 million for Life Sciences in 2025.
(c)
Includes a capital projects impairment charge of $11 million for Personal Care in 2024.
(d)
Includes a $2 million capital projects impairment charge in 2026 and a goodwill impairment of $331 million for Specialty Additives in 2025.
(e)
Includes a $3 million gain on sale of excess corporate property, a $2 million excess land contract termination fee income and a $13 million Argentina foreign currency cumulative translation adjustment in 2026, $8 million gain on sale and a $183 million impairment charge related to the divestiture of the Avoca business in 2025, and a $8 million loss on sale and a $99 million impairment charge related to the divestiture of the Nutraceuticals business in 2024 within the loss on divestitures, net.
(f)
Depreciation includes accelerated depreciation of $21 million for Life Sciences in 2025.
(g)
Depreciation includes accelerated depreciation of $1 million, $1 million and $2 million for Personal Care in 2026, 2025 and 2024, respectively.
(h)
Depreciation includes accelerated depreciation of $3 million, $19 million and $55 million for Specialty Additives in 2026, 2025 and 2024, respectively.
(i)
Depreciation includes accelerated depreciation of $1 million for Unallocated and other in 2026.
(j)
Excludes loss from discontinued operations, net of income taxes and other net periodic benefit (income) loss. See the Statements of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.

M-21

Life Sciences

Life Sciences is composed of pharmaceuticals, nutrition, agricultural chemicals, diagnostic films (formerly known as advanced materials) and fine chemicals. Pharmaceutical solutions include controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers and tablet binders. Nutrition solutions include thickeners, stabilizers, emulsifiers and additives for enhancing mouthfeel, controlling moisture migration, reducing oil uptake and binding structured foods. Customers include pharmaceutical, food, and beverage manufacturers, hospitals and radiologists manufacturers. The Nutraceuticals business was sold in August 2024. See Note B of the Notes to Consolidated Financial Statements for more information.

The following table provides a reconciliation of the change in sales for Life Sciences between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Sales change

Volume

$

22

$

(40

)

Foreign Currency

8

1

Divestiture

-

(109

)

Price/mix

-

(21

)

$

30

$

(169

)

The following table provides a reconciliation of the change in operating income (loss) for Life Sciences between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Operating income (loss) change

Goodwill impairment

$

375

$

(375

)

Volume

12

(9

)

Price/mix

8

(20

)

Foreign Currency

3

2

Costs

(5

)

(21

)

Divestiture

-

(7

)

$

393

$

(430

)

EBITDA and Adjusted EBITDA reconciliation

The EBITDA and Adjusted EBITDA amounts presented within this business section are provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for each segment. Each of these non-GAAP financial measures is defined as follows: EBITDA (operating income (loss) plus depreciation and amortization), Adjusted EBITDA (EBITDA adjusted for key items as applicable), and Adjusted EBITDA margin (Adjusted EBITDA divided by sales). Ashland does not allocate items to each reportable segment below operating income (loss), such as interest expense and income taxes. As a result, reportable segment EBITDA and Adjusted EBITDA are reconciled directly to operating income (loss) since it is the most directly comparable Statements of Consolidated Comprehensive Income (Loss) caption.

The following EBITDA presentation for the years ended September 30, 2026, 2025 and 2024, is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Life Sciences. There were key items for the years ended

M-22

September 30, 2026, 2025 and 2024. These items are listed below and described within the "Use of Non-GAAP Financial Measures" section above.

2026

2025

(In millions)

2026

2025

2024

change

change

Operating income (loss)

$

131

$

(262

)

$

168

$

393

$

(430

)

Depreciation and amortization(a)

56

54

64

2

(10

)

EBITDA

187

(208

)

232

395

(440

)

Goodwill impairment

-

375

-

(375

)

375

Accelerated depreciation

-

21

-

(21

)

21

Other plant optimization costs

2

5

-

(3

)

5

Asset impairment

16

-

-

16

-

Environmental remediation reserves adjustments

-

-

1

-

(1

)

Held for sale depreciation and amortization

-

-

(3

)

-

3

Adjusted EBITDA

$

205

$

193

$

230

$

12

$

(37

)

Operating income (loss) as a percent of sales

19.5

%

-40.9

%

20.7

%

6040 bps

Not meaningful

Adjusted EBITDA as a percent of sales

30.6

%

30.1

%

28.4

%

50 bps

170 bps

(a)
Depreciation and amortization for Life Sciences excludes accelerated depreciation of $21 million in 2025 and includes $3 million associated with the Nutraceuticals business in 2024 which is included as a key item within this table as a component of Adjusted EBITDA.

2026 compared to 2025

Life Sciences' sales increased primarily due to higher volume and favorable foreign currency exchange. Operating income (loss) increased as a result of the prior period goodwill impairment, higher volume, favorable foreign currency exchange and favorable price/mix, partially offset by higher costs. 2026 includes a capital project impairment charge of $16 million. Adjusted EBITDA increased as a result of higher volume, favorable foreign currency exchange and favorable price/mix, partially offset by higher costs.

2025 compared to 2024

Life Sciences' sales, operating income (loss) and Adjusted EBITDA decreased in 2025 primarily due to the divestiture of the Nutraceuticals business, lower volume, and unfavorable pricing, partially offset by favorable foreign currency exchange. Operating income (loss) for 2025 also included a goodwill impairment charge of $375 million and higher costs of $26 million for Portfolio Optimization actions.

Personal Care

Personal Care is composed of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household solutions. These businesses have a broad range of natural, nature-derived, biodegradable, and high-performance ingredients for customer driven solutions to help protect, renew, moisturize and revitalize skin and hair, and provide solutions for toothpastes, mouth washes and rinses, denture cleaning and care for teeth. Personal Care supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers for household, industrial and institutional cleaning products. Customers include formulators at large multinational branded consumer products companies and smaller, independent boutique companies. The Avoca business was sold in March 2025. See Note B of the Notes to Consolidated Financial Statements for more information.

M-23

The following table provides a reconciliation of the change in sales for Personal Care between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Sales change

Volume

$

24

$

(8

)

Foreign Currency

9

4

Divestiture

(11

)

(44

)

Price/mix

(7

)

(9

)

$

15

$

(57

)

The following table provides a reconciliation of the change in operating income for Personal Care between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Operating income change

Volume

$

9

$

(1

)

Price/mix

4

(9

)

Divestiture (site closure)

4

(1

)

Foreign Currency

3

2

Costs

(9

)

26

$

11

$

17

EBITDA and Adjusted EBITDA reconciliation

The following EBITDA presentation (as defined and described in the section above) for the years ended September 30, 2026, 2025 and 2024, is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Personal Care. There were key items for the years ended September 30, 2026, 2025 and 2024. These items are listed below and described within the "Use of Non-GAAP Financial Measures" section above.

2026

2025

(In millions)

2026

2025

2024

change

change

Operating income

$

101

$

90

$

73

$

11

$

17

Depreciation and amortization(a)

59

66

77

(7

)

(11

)

EBITDA

160

156

150

4

6

Other plant optimization costs

2

3

1

(1

)

2

Accelerated depreciation

1

1

2

-

(1

)

Held for sale depreciation and amortization

-

(2

)

-

2

(2

)

Asset impairment

-

-

11

-

(11

)

Adjusted EBITDA

$

163

$

158

$

164

$

5

$

(6

)

Operating income as a percent of sales

17.1

%

15.6

%

11.5

%

150 bps

410 bps

Adjusted EBITDA as a percent of sales

27.5

%

27.4

%

25.9

%

10 bps

150 bps

(a)
Depreciation and amortization for Personal Care includes $2 million associated with the Avoca business in 2025 and excludes accelerated depreciation of $1 million, $1 million, and $2 million in 2026, 2025, and 2024, respectively, which is included as a key item within this table as a component of Adjusted EBITDA.

2026 compared to 2025

M-24

Personal Care's sales increased as a result of higher volume and favorable foreign currency exchange, partially offset by unfavorable price/mix and the impact of the Avoca business divestiture. Operating income for the current year increased primarily due to higher volume, favorable price/mix, favorable foreign currency exchange and the impact of the Avoca business divestiture, partially offset by higher costs. Adjusted EBITDA increased primarily due to higher volume, favorable price/mix, the positive impact of the Avoca business divestiture and favorable foreign currency exchange, partially offset by higher costs.

2025 compared to 2024

Personal Care's sales and Adjusted EBITDA decreased in 2025 primarily due to lower volume, including the divestiture of the Avoca business and other Portfolio Optimization actions, and unfavorable price/mix, partially offset by lower costs and favorable foreign exchange currency. Operating income increased due to lower costs and favorable foreign exchange currency, partially offset by unfavorable price/mix.

Specialty Additives

Specialty Additives is composed of rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive and various industrial markets. Solutions include coatings additives for architectural paints, finishes and lacquers, cement- and gypsum-based dry mortars, ready-mixed joint compounds, synthetic plasters for commercial and residential construction, and specialty materials for industrial applications. Products include rheology modifiers (cellulosic and associative thickeners), foam control agents, surfactants and wetting agents, pH neutralizers and environmental filters, ingredients that aid the manufacturing process of ceramic capacitors, advanced ceramics used in catalytic converters, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals and alloys for welding. Products help improve desired functional outcomes through rheology modification and control, water retention, workability, adhesive strength, binding power, film formation, deposition and suspension and emulsification. Customers include, but are not limited to, global paint manufacturers, electronics and automotive manufacturers, textile mills, the construction industry and welders.

The following table provides a reconciliation of the change in sales for Specialty Additives between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Sales change

Volume

$

(17

)

$

(56

)

Foreign Currency

7

2

Price/mix

3

(7

)

Divestiture

-

-

$

(7

)

$

(61

)

M-25

The following table provides a reconciliation of the change in operating loss for Specialty Additives between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Operating income (loss) change

Goodwill impairment

$

331

$

(331

)

Price/mix

8

(10

)

Costs

(9

)

46

Foreign Currency

(2

)

(1

)

Volume

(2

)

(10

)

Divestiture

-

-

$

326

$

(306

)

EBITDA and Adjusted EBITDA reconciliation

The following EBITDA presentation (as defined and described in the section above) for the years ended September 30, 2026, 2025 and 2024 below is provided as a means to enhance the understanding of financial measurements that Ashland has internally determined to be relevant measures of comparison for the results of Specialty Additives. There were key items for the years ended September 30, 2026, 2025 and 2024. These items are listed below and described within the "Use of Non-GAAP Financial Measures" section above.

2026

2025

(In millions)

2026

2025

2024

change

change

Operating loss

$

(12

)

$

(338

)

$

(32

)

$

326

$

(306

)

Depreciation and amortization(a)

60

65

66

(5

)

(1

)

EBITDA

48

(273

)

34

321

(307

)

Goodwill impairment

-

331

-

(331

)

331

Accelerated depreciation

3

19

55

(16

)

(36

)

Other plant optimization costs

17

15

9

2

6

Environmental remediation reserves adjustments

-

2

1

(2

)

1

Asset impairment

2

-

-

2

-

Adjusted EBITDA

$

70

$

94

$

99

$

(24

)

$

(5

)

Operating loss as a percent of sales

-2.4

%

-66.1

%

-5.6

%

6370 bps

Not meaningful

Adjusted EBITDA as a percent of sales

13.9

%

18.4

%

17.3

%

-450 bps

110 bps

(a)
Depreciation and amortization for Specialty Additives excludes accelerated depreciation of $3 million, $19 million, and $55 million in 2026, 2025, and 2024, respectively, which is included as a key item within this table as a component of Adjusted EBITDA.

M-26

2026 compared to 2025

Specialty Additives sales in 2026 decreased primarily due to lower volume, partially offset by favorable price/mix and favorable foreign exchange currency. Operating loss decreased as a result of the prior period goodwill impairment and favorable price/mix, partially offset by higher costs, lower volume and unfavorable foreign currency exchange. Adjusted EBITDA in 2026 decreased primarily due to higher costs, lower volume and unfavorable foreign currency exchange partially offset by favorable price/mix.

2025 compared to 2024

Specialty Additives sales and EBITDA in 2025 decreased primarily due to lower volume and unfavorable price/mix partially offset by favorable foreign exchange currency. Operating loss increased and Adjusted EBITDA decreased in 2025 primarily due to lower volume and unfavorable price/mix partially offset by lower costs, including the effects of portfolio optimization activities and accelerated depreciation. Operating loss for 2025 included a goodwill impairment charge of $331 million.

Intermediates

Intermediates is composed of the production of 1,4 butanediol ("BDO") and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, agriculture, pharmaceuticals, water filtration membranes and more. BDO is also supplied to Life Sciences, Personal Care, and Specialty Additives for use as a raw material.

The following table provides a reconciliation of the change in sales for Intermediates between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Sales change

Volume

$

(3

)

$

7

Foreign Currency

1

1

Price/mix

-

(15

)

$

(2

)

$

(7

)

The following table provides a reconciliation of the change in operating income for Intermediates between 2026 and 2025 and between 2025 and 2024.

(In millions)

2026 change

2025 change

Operating income change

Cost

$

4

$

(1

)

Price/mix

1

(23

)

Foreign Currency

1

-

Volume

(3

)

3

$

3

$

(21

)

EBITDA reconciliation

The following EBITDA presentation (as defined and described in the section above) for the years ended September 30, 2026, 2025 and 2024 is provided as a means to enhance the understanding of financial

M-27

measurements that Ashland has internally determined to be relevant measures of comparison for the results of Intermediates. Intermediates had no key items for the years ended September 30, 2026, 2025 and 2024.

2026

2025

(In millions)

2026

2025

2024

change

change

Operating income

$

11

$

8

$

29

$

3

$

(21

)

Depreciation and amortization

5

13

13

(8

)

-

EBITDA

16

21

42

(5

)

(21

)

Operating income as a percent of sales

8.1

%

5.8

%

20.1

%

230 bps

-1430 bps

EBITDA as a percent of sales

11.9

%

15.3

%

29.2

%

-340 bps

-1390 bps

2026 compared to 2025

Intermediates' sales decreased due to lower volume partially offset by favorable foreign currency exchange. Operating income increased primarily due to lower costs, favorable price/mix and favorable foreign currency exchange, partially offset by lower volume. EBITDA decreased in the current year period primarily due to lower volume and higher costs partially offset by favorable foreign currency exchange and favorable price/mix.

2025 compared to 2024

Intermediates' sales, operating income and EBITDA for 2025 decreased primarily due to unfavorable price/mix partially offset by higher volume.

Unallocated and other

The following table summarizes the key components of the Unallocated and other's operating loss for the years ended September 30:

2026

2025

(In millions)

2026

2025

2024

change

change

Restructuring activities

$

(23

)

$

(22

)

$

(30

)

$

(1

)

$

8

Environmental expenses

(33

)

(32

)

(43

)

(1

)

11

Accelerated depreciation

(1

)

-

-

(1

)

-

Tax credit

8

3

-

5

3

Loss on divestitures, net

(8

)

(161

)

(115

)

153

(46

)

Argentina currency devaluation impact

-

-

(5

)

-

5

Other expenses (primarily governance and legacy expenses)

(68

)

(61

)

(71

)

(7

)

10

$

(125

)

$

(273

)

$

(264

)

$

148

$

(9

)

The charges for restructuring activities of $23 million, $22 million and $30 million during 2026, 2025 and 2024, respectively, were primarily composed of severance, lease abandonment and other restructuring costs related to company-wide cost reduction programs.

Environmental expenses of $33 million, $32 million and $43 million during 2026, 2025 and 2024, respectively, are primarily driven by specific remediation site estimated costs during the periods.

The remaining items included: accelerated depreciation of $1 million, a tax credit of $8 million and $8 million loss on divestitures (includes $3 million income on excess corporate real estate sales, a $2 million excess land property termination fee and $13 million Argentina foreign currency cumulative translation adjustment) in 2026,

M-28

loss on divestitures of $161 million (primarily related to the $183 million impairment of the Avoca business, $8 million pre-tax gain on the final sale of the Avoca business, and $14 million gain on sale of a property) and a tax credit of $3 million in 2025, and expense of $5 million related to the devaluation of the currency in Argentina and loss on divestiture of $115 million (primarily related to the $107 million impairment charge and loss on sale associated with the Nutraceuticals business as well as a $7 million charge related to Nutraceutical VAT reserves) in 2024.

Other expenses between periods were driven by increases and decreases in governance and legacy expenses associated with foreign currency, deferred compensation, stock compensation and incentive compensation.

M-29

FINANCIAL POSITION

Liquidity

Ashland had $480 million in cash and cash equivalents as of September 30, 2026, of which $387 million was held by foreign subsidiaries and had no significant limitations that would prohibit remitting the funds to satisfy corporate obligations. In certain circumstances, if such amounts were repatriated to the United States, additional withholding taxes might need to be accrued and paid depending on the source of the earnings remitted. Ashland currently has no plans to repatriate any amounts for which additional taxes would need to be accrued.

Ashland has taken actions and may continue to take actions intended to increase its cash and cash equivalents position and preserve financial flexibility. At September 30, 2026, Ashland has total remaining borrowing capacity of $496 million available under the Revolving Credit Facility. Ashland had no available liquidity under the U.S. and Foreign Accounts Receivable Sales Program, as of September 30, 2026. Ashland has no significant maturities related to revolving credit facilities or bonds until fiscal 2028.

On September 24, 2026, Ashland, through Ashland International Receivables Designated Activity Company, an Ireland-based, a wholly-owned, bankruptcy-remote consolidated special purpose entity ("SPE"), entered into a Deed of Amendment and Restatement (the "Amendment") of the Foreign Accounts Receivable Sale Program. Pursuant to the Amendment, the parties amended and restated the program's Purchase Agreement and Master Framework Agreement, each originally dated October 19, 2023. The Amendment extends the program until September 21, 2029. The facility continues to provide for the sale of eligible trade receivables under a revolving receivables securitization program having an aggregate facility limit of €125 million. In connection with the Amendment, Bank of America, N.A. assigned, transferred and delegated all of its rights, interests and obligations as committed purchaser to Bank of America Europe DAC. Bank of America, N.A. continues to serve as administrative agent under the facility. The Amendment also includes certain additional updates to the Foreign Accounts Receivable Sale Program that are consistent with current market standards.

As part of this amendment the buyer's limit was maintained at €125 million through the termination date of the agreement on September 21, 2029. Under the agreement, Ashland can transfer whole receivables up to a limit established by the buyer, which is currently set at a maximum of €125 million subject to other limitations as applicable. Ashland accounts for accounts receivable transferred to buyers as part of this agreement as sales. See Note H of the Notes to Consolidated Financial Statements for more information on the Foreign Accounts Receivables Sale Program.

On July 30, 2026, Ashland entered into a Fifth Amendment associated with the U.S. Accounts Receivable Sale Program. As part of this amendment the buyer's limit was maintained at $70 million through the termination date of the agreement. Additionally, the scheduled termination date was extended from September 11, 2026 to July 28, 2028. Under the agreement, Ashland can transfer whole accounts receivable up to a limit established by the buyer, which is currently set at a maximum of $70 million subject to other limitations as applicable. Ashland accounts for accounts receivable transferred to buyers as part of this agreement as sales. See Note H of the Notes to Consolidated Financial Statements for more information on the U.S. Accounts Receivable Sale Program.

M-30

During May 2026, Ashland entered into a Second Amended and Restated Credit Agreement (the "2026 Credit Agreement"). The 2026 Credit Agreement provides for a $500 million five-year revolving credit facility (including a $125 million letter of credit sublimit) (the "2026 Revolving Credit Facility"). Proceeds of borrowings under the 2026 Revolving Credit Facility are intended to provide ongoing working capital and for other general corporate purposes. See Note H of the Notes to Consolidated Financial Statements for more information.

During April 2024, Ashland authorized a financing program offered through JP Morgan and Taulia Alliance. Under this program, JP Morgan and its affiliates may purchase certain confirmed receivables directly from suppliers pursuant to the terms of a separate arrangement entered into between JPMorgan and Taulia Alliance and such suppliers. There were no changes to Ashland's standard payment terms with its suppliers in connection with this program. Ashland provides no guarantees to JP Morgan and Taulia Alliance under this program. The program was implemented during June 2025 and has been actively offered to suppliers. Participation in the program has not been significant. There were $20 million and less than $1 million of confirmed invoices under this program for the years ended September 30, 2026 and 2025, respectively.

The company currently expects to refinance the 2.00% senior notes prior to their January 2028 maturity and will evaluate available financing alternatives, including partial pay down, based on the prevailing market conditions.

Ashland believes that cash flow from operations, availability under existing credit facilities and arrangements, current cash and investment balances and the ability to obtain other financing, if necessary, will provide adequate cash funds for Ashland's foreseeable working capital needs, capital expenditures at existing facilities, dividend payments and debt service obligations. Ashland's cash requirements are subject to change as business conditions warrant and opportunities arise. The timing and size of any new business ventures or acquisitions that the Company may complete may also impact its cash requirements.

Ashland's cash flows from operating, investing and financing activities, as reflected in the Statements of Consolidated Cash Flows, are summarized as follows, for the years ended September 30:

(In millions)

2026

2025

2024

Cash provided (used) by:

Operating activities from continuing operations

$

385

$

134

$

462

Investing activities from continuing operations

8

(3

)

(51

)

Financing activities from continuing operations

(81

)

(179

)

(479

)

Discontinued operations

(46

)

(40

)

(51

)

Effect of currency exchange rate changes on cash and cash equivalents

(1

)

3

2

Net increase (decrease) in cash and cash equivalents

$

265

$

(85

)

$

(117

)

Ashland received income tax refunds of $58 million during 2026 (includes receipts of a tax refund related to the capital loss carryback from the Nutraceutical business sale of $103 million), compared to income taxes paid of $33 million in 2025 and $53 million in 2024. Cash receipts for interest income were $6 million in 2026, $5 million in 2025, and $10 million in 2024, while cash payments for interest expense amounted to $53 million in 2026, $54 million in 2025 and $52 million in 2024.

M-31

Operating activities

The following summarizes the cash flows associated with Ashland's operating activities for the years ended September 30:

(In millions)

2026

2025

2024

Cash flows provided by operating activities from continuing operations

Net income (loss)

$

4

$

(845

)

$

169

Loss from discontinued operations, net of income taxes

21

23

30

Adjustments to reconcile income (loss) from continuing operations to cash flows from operating activities

Depreciation and amortization

185

237

274

Original issue discount and debt issuance cost amortization

8

7

6

Deferred income taxes

7

73

(302

)

Gain from sales of property and equipment

(5

)

(16

)

-

Equity income from affiliates

(1

)

-

-

Stock based compensation expense

18

14

15

Loss from excess tax deduction on stock based compensation

(1

)

(3

)

-

Income from restricted investments

(21

)

(33

)

(74

)

Loss on divestitures, net

13

177

107

Goodwill impairment

-

706

-

Asset impairments

18

-

11

Pension contributions

(12

)

(12

)

(15

)

(Gain) loss on pension and other postretirement plan remeasurements

(7

)

(3

)

14

Change in operating assets and liabilities(a)

158

(191

)

227

Total cash flows provided by operating activities from continuing operations

$

385

$

134

$

462

(a)
Excludes changes resulting from operations acquired or sold.

Operating Activities - Operating Assets and Liabilities

The cash results during each year were primarily driven by net income (loss), excluding discontinued operation results, adjusted for certain non-cash items including depreciation and amortization (including debt issuance cost amortization), loss on divestitures, net as well as changes in working capital, which are fluctuations within accounts receivable, inventories and trade and other payables.

The following details certain changes in key operating assets and liabilities for the years ended September 30:

(In millions)

2026

2025

2024

Cash flows from assets and liabilities(a)

Accounts receivable

$

(25

)

$

(3

)

$

96

Inventories

87

(28

)

79

Trade and other payables

26

(63

)

56

Other assets and liabilities

70

(97

)

(4

)

Change in operating assets and liabilities

$

158

$

(191

)

$

227

(a)
Excludes changes resulting from operations acquired or sold.

M-32

Changes in net working capital accounted for inflows of $88 million in 2026, outflows of $94 million in 2025, and inflows of $231 million in 2024, and were driven by the following:

•
Accounts receivable - Changes in accounts receivable resulted in outflows of $25 million, outflows of $3 million and inflows of $96 million in 2026, 2025 and 2024, respectively. The U.S. Accounts Receivable Sale Program contributed to inflows of $9 million, outflows of $12 million, and inflows of $1 million 2026, 2025 and 2024, respectively. The Foreign Accounts Receivable Sale Program contributed to inflows of $9 million, outflows of $6 million and inflows of $104 million in 2026, 2025 and 2024, respectively. Sales volumes in each period and activity from the U.S. and Foreign Accounts Receivable Sale Programs were the main drivers of changes between periods.
•
Inventories - Changes in inventory resulted in cash inflows of $87 million in 2026, outflows of $28 million in 2025 and inflows of $79 million in 2024 and were primarily driven by inventory production levels and volumes.
•
Trade and other payables - Changes in trade and other payables resulted in cash inflows of $26 million in 2026, cash outflows of $63 million in 2025, and cash inflows of $56 million in 2024, and primarily related to restructuring activity, divestitures and the timing of certain other payments.

The remaining cash inflows of $70 million, cash outflows of $97 million, and cash outflows of $4 million in 2026, 2025 and 2024, respectively, were primarily due to income taxes paid or income tax refunds, interest paid, and adjustments to other assets and liabilities such as payments associated with environmental remediation. 2025 includes the impact of refundable income taxes recorded within 2025 that were received in 2026 in the amount of $103 million.

Investing activities

The following summarizes the cash flows associated with Ashland's investing activities for the years ended September 30:

(In millions)

2026

2025

2024

Cash flows provided (used) by investing activities from continuing operations

Additions to property, plant and equipment

$

(88

)

$

(98

)

$

(137

)

Proceeds from disposal of property, plant and equipment

6

16

-

Proceeds from sale or restructuring of operations

2

16

26

Proceeds from settlement of company-owned life insurance contracts

27

12

1

Company-owned life insurance payments

(4

)

(5

)

(5

)

Funds restricted for specific transactions

(9

)

(8

)

(5

)

Reimbursement from restricted investments

74

62

79

Proceeds from sale of securities

71

56

53

Purchase of securities

(71

)

(54

)

(53

)

Other investing cash flows

-

-

(10

)

Total cash flows provided (used) by investing activities from continuing operations

$

8

$

(3

)

$

(51

)

The significant cash investing activities for 2026 primarily related to cash outflows of $88 million for capital expenditures, inflows of $27 million for the settlement of company-owned life insurance policies and $9 million restricted for investment trust purposes for environmental remediation. Additionally, there were inflows of $6

M-33

million of proceeds from the sale of land property and $2 million of proceeds from the sale of the Avoca business and reimbursements of $74 million from the restricted renewable annual investment trusts.

The significant cash investing activities for 2025 primarily related to cash outflows of $98 million for capital expenditures and $8 million restricted for investment trust purposes for environmental remediation. Additionally, there were inflows of $16 million from proceeds from the sale of the Avoca business, $16 million of proceeds from the sale of land property, $12 million of proceeds from settlement of company-owned life insurance contracts and reimbursements of $62 million from the restricted renewable annual investment trusts.

The significant cash investing activities for 2024 primarily related to cash outflows of $137 million for capital expenditures, $10 million for lease asset acquisition and $5 million restricted for investment trust purposes for environmental remediation. Additionally, there were inflows of $26 million from the sale of the Nutraceuticals business and reimbursements of $79 million from the restricted renewable annual investment trusts.

Financing activities

The following summarizes the cash flows associated with Ashland's financing activities for the years ended September 30:

(In millions)

2026

2025

2024

Cash flows used by financing activities from continuing operations

Repayment of short-term debt

-

-

(16

)

Repurchase of common stock

-

(100

)

(380

)

Debt issuance costs

(2

)

-

-

Cash dividends paid

(76

)

(76

)

(78

)

Stock based compensation employee withholding taxes paid in cash

(3

)

(3

)

(5

)

Total cash flows used by financing activities from continuing operations

$

(81

)

$

(179

)

$

(479

)

Significant cash financing activities for 2026 included outflows of cash dividends paid of $1.67 per share, for a total of $76 million.

Significant cash financing activities for 2025 included outflows of $100 million for common stock repurchases and cash dividends paid of $1.64 per share, for a total of $76 million.

Significant cash financing activities for 2024 included outflows of $380 million for common stock repurchases, short-term debt repayment of $16 million, and cash dividends paid of $1.58 per share, for a total of $78 million.

Cash used by discontinued operations

The following summarizes the cash flows associated with Ashland's discontinued operations for the years ended September 30:

(In millions)

2026

2025

2024

Cash used by discontinued operations

Operating cash flows

$

(46

)

$

(40

)

$

(51

)

Total cash used by discontinued operations

$

(46

)

$

(40

)

$

(51

)

Cash outflows for discontinued operations in 2026, 2025 and 2024 primarily related to retained liabilities for asbestos and environmental claims directly related to divested businesses that have qualified as discontinued

M-34

operations. Asbestos net payments were $39 million, $36 million and $39 million in 2026, 2025 and 2024, respectively. Environmental net payments were $6 million, $4 million and $6 million, respectively. The remaining net cash outflows in each period primarily relate to tax and other post closing adjustments.

Free Cash Flow and other liquidity resources

The following represents Ashland's calculation of Free Cash Flow and Ongoing Free Cash Flow for the years ended September 30. Free Cash Flow does not reflect adjustments for certain non-discretionary cash flows such as mandatory debt repayments.

(In millions)

2026

2025

2024

Total cash flows provided by operating activities from continuing operations

$

385

$

134

$

462

Adjustments:

Additions to property, plant and equipment

(88

)

(98

)

(137

)

Free Cash Flow

297

36

325

Tax refund(a)

(103

)

-

-

Cash (inflows) outflows from U.S. Accounts Receivable Sale Program(b)

(9

)

12

(1

)

Cash (inflows) outflows from Foreign Accounts Receivable Sale Program(c)

(9

)

6

(104

)

Restructuring-related payments(d)

23

34

14

Environmental and related litigation payments(e)

33

39

36

Ongoing Free Cash Flow

$

232

$

127

$

270

Net income (loss)

4

(845

)

169

Adjusted EBITDA(f)

385

401

459

Operating Cash Flow Conversion(g)

Not meaningful

Not meaningful

273

%

Ongoing Free Cash Flow Conversion(h)

60

%

32

%

59

%

(a)
Represents receipt of tax refund related to the capital loss carryback from the Nutraceutical business divestiture.
(b)
Represents activity associated with the U.S. Accounts Receivable Sale Program impacting each period presented.
(c)
Represents activity associated with the Foreign Accounts Receivable Sale Program impacting each period presented.
(d)
Restructuring payments incurred during each period.
(e)
Represents cash outflows associated with environmental and related litigation payments which will be reimbursed by the environmental trust.
(f)
See Adjusted EBITDA reconciliation.
(g)
Operating Cash Flow Conversion is defined as Cash flows provided by operating activities from continuing operations divided by net income (loss).
(h)
Ongoing Free Cash Flow Conversion is defined as Ongoing Free Cash Flow divided by Adjusted EBITDA.

Working capital (current assets minus current liabilities, excluding long-term debt due within one year) amounted to $888 million and $782 million as of September 30, 2026 and 2025, respectively. The $106 million increase in working capital was driven by an increase in cash and cash equivalents, partially offset by a lower trade working capital (accounts receivable and inventories minus trade and other payables and accrued expenses and other liabilities), including sales of foreign accounts receivable under the Foreign Accounts Receivable Sale Program, and other assets. The increase in Ongoing Free Cash Flows was primarily a result of favorable working capital, lower additions to property, plant and equipment and lower variable compensation payouts between periods. Liquid assets (cash and cash equivalents and accounts receivable) amounted to 165% and 108% of current liabilities as of September 30, 2026 and 2025, respectively.

M-35

The following summary reflects Ashland's cash and cash equivalents, investment securities and unused borrowing capacity as of September 30:

(In millions)

2026

2025

Cash, cash equivalents and investment securities

Cash and cash equivalents

$

480

$

215

Restricted investments(a)

304

347

Unused borrowing capacity

Revolving Credit Facility

$

496

$

596

U.S. Accounts Receivable Sales Program

-

-

Foreign Accounts Receivable Sales Program

-

-

(a)
Includes $208 million and $231 million related to the Asbestos trust and $96 million and $116 million related to the Environmental trust as of September 30, 2026 and 2025, respectively.

The borrowing capacity remaining under the 2026 Credit Agreement was $496 million, which reflects the full $500 million 2026 Revolving Credit Facility less a reduction of $4 million for letters of credit outstanding at September 30, 2026. In total, Ashland's available liquidity position, which includes cash and cash equivalents and the 2026 Revolving Credit Facility (2022 Revolving Credit Facility for fiscal 2025), was $976 million and $811 million at September 30, 2026 and 2025, respectively. Ashland had zero available liquidity under the U.S. and Foreign Accounts Receivable Sale Program as of September 30, 2026. Ashland also maintained $304 million and $347 million of restricted investments at September 30, 2026 and 2025, respectively, to pay for future asbestos claims and environmental remediation and related litigation.

Capital resources

Debt

The following summary reflects Ashland's debt as of September 30:

(In millions)

2026

2025

Current portion of long-term debt

$

4

$

-

Long-term debt (less current portion and debt issuance cost discounts)(a)

1,367

1,384

Total debt

$

1,371

$

1,384

(a)
Includes $8 million and $10 million of debt issuance cost discounts as of September 30, 2026 and 2025, respectively.

Ashland continues to maintain the 2026 Credit Agreement which provides for a $500 million five-year revolving credit facility. Proceeds of borrowings under the 2026 Revolving Credit Facility provide ongoing working capital and are used for other general corporate purposes.

Debt as a percent of capital employed was 43% and 42% at September 30, 2026 and 2025, respectively. At September 30, 2026, Ashland's total debt had an outstanding principal balance of $1,398 million, discounts of $19 million and debt issuance costs of $8 million. Ashland has debt maturities of (excluding debt issuance costs) $4 million due in fiscal 2027, $566 million due in fiscal 2028, $97 million in 2029, zero in 2030 and $450 million in 2031.

M-36

Credit Agreements and Refinancing

2026 Credit Agreement

On May 28, 2026 (the "Closing Date"), Ashland Inc. and its Swiss subsidiary, Ashland Industries Europe GmbH ("the Swiss Borrower"), entered into the 2026 Credit Agreement, which provides the 2026 Revolving Credit Facility that may be drawn by Ashland or the Swiss Borrower.

The 2026 Credit Agreement amends and restates the Amended and Restated Credit Agreement dated as of July 22, 2022.

The obligations of the Swiss Borrower under the 2026 Revolving Credit Facility are guaranteed by Ashland. The 2026 Revolving Credit Facility is unsecured.

At Ashland's option, loans issued under the 2026 Credit Agreement will bear interest at (a) in the case of loans denominated in U.S. dollars, either Term Secured Overnight Financing Rate ("SOFR") or an alternate base rate and (b) in the case of loans denominated in Euros, Euro Interbank Offered Rate ("EURIBOR"), in each case plus the applicable interest rate margin. Loans will initially bear interest at Term SOFR or EURIBOR plus 1.375% per annum, in the case of Term SOFR borrowings or EURIBOR borrowings, respectively, or at the alternate base rate plus 0.375%, in the case of alternate base rate borrowings, through and including the date of delivery of a quarterly compliance certificate and thereafter the interest rate will fluctuate between Term SOFR or EURIBOR plus 1.250% per annum and Term SOFR or EURIBOR plus 1.750% per annum (or between the alternate base rate plus 0.250% per annum and the alternate base rate plus 0.750% per annum), based upon the Consolidated Net Leverage Ratio (as defined in the 2026 Credit Agreement) at such time. In addition, Ashland will initially be required to pay fees of 0.175% per annum on the daily unused amount of the 2026 Revolving Credit Facility through and including the date of delivery of a compliance certificate, and thereafter the fee rate will fluctuate between 0.125% and 0.275% per annum, based upon the Consolidated Net Leverage Ratio.

The 2026 Revolving Credit Facility may be prepaid at any time without premium.

The 2026 Credit Agreement contains usual and customary representations and warranties, and usual and customary affirmative and negative covenants, including limitations on liens, additional subsidiary indebtedness, investments, mergers, dispositions, restricted payments, changes in the nature of business, affiliate transactions, restrictions on distributions by subsidiaries, use of proceeds, accounting changes and other customary limitations, as well as financial covenants (including maintenance of a maximum Consolidated Net Leverage Ratio and a minimum Consolidated Interest Coverage Ratio (as defined in the 2026 Credit Agreement)). The 2026 Credit Agreement also contains usual and customary events of default, including non-payment of principal, interest, fees and other amounts, material breach of a representation or warranty, non-performance of covenants and obligations, default on other material debt, bankruptcy or insolvency, material judgments, incurrence of certain material ERISA liabilities, impairment of loan documentation and change of control.

Ashland incurred and paid $2 million of debt issuance costs in connection with the 2026 Credit Agreement during the fiscal 2026. These costs are being amortized over the term of the 2026 Credit Agreement using the straight-line method and are included within net interest and other expense (income) in the Statements of Consolidated Comprehensive Income (Loss). This amount was also recorded within debt issuance costs paid in

M-37

the cash flows used by financing activities from continuing operations section of the Statement of Consolidated Cash Flows for the year ended September 30, 2026.

Cash repatriation

During 2026 and 2025, Ashland repatriated approximately $5 million and $403 million, respectively, in cash.

Accounts receivable facilities and off-balance sheet arrangements

U.S. Accounts Receivable Sale Program

On March 17, 2021, a wholly-owned, bankruptcy-remote special purpose entity and consolidated Ashland subsidiary ("SPE") entered into an agreement with a group of entities (buyers) to sell certain accounts receivable, without recourse beyond the pledged receivables, of two other U.S. based Ashland subsidiaries. Under the agreement, Ashland can transfer whole accounts receivable up to a limit established by the buyer, which was set at $125 million between February and October of each year and up to $100 million all other times (a level 1 fair value measurement). Ashland's continuing involvement is limited to servicing the accounts receivable, including billing, collections and remittance of payments to the buyers as well as a limited guarantee on over-collateralization. The arrangement was set to terminate on May 31, 2023.

On April 14, 2023, Ashland entered into a Second and Third Amendments associated with this current program. As part of this amendment the buyer's limit was reduced to $115 million between April and October of each year, and up to $100 million at all other times. Additionally, the scheduled termination date was extended from May 31, 2023 to April 14, 2025.

On September 13, 2024, Ashland entered into a Fourth Amendment associated with this current program. As part of this amendment the buyer's limits were reduced to $80 million between September 13, 2024 to (and including) December 31, 2024 and up to $70 million from January 1, 2025 through the termination date of the agreement. Additionally, the scheduled termination date was extended from April 14, 2025 to September 11, 2026.

On July 30, 2026, Ashland entered into a Fifth Amendment associated with this current program. As part of this amendment the buyer's limit was maintained at $70 million through the termination date of the agreement. Additionally, the scheduled termination date was extended from September 11, 2026 to July 28, 2028.

Ashland determined that any accounts receivable transferred under this agreement are put presumptively beyond the reach of Ashland and its creditors, even in bankruptcy or other receivership. Ashland received a true sale at law and non-consolidation opinions to support the legal isolation of these accounts receivable. Ashland accounts for the accounts receivable transferred to buyers as sales. Ashland recognizes any gains or losses based on the excess of proceeds received net of buyer's discounts and fees compared to the carrying value of the assets. Proceeds received, net of buyer's discounts and fees, are recorded within the operating activities of the Statements of Consolidated Cash Flows. Losses on sale of assets, including related transaction expenses are recorded within the net interest and other expense (income) caption of the Statements of Consolidated Comprehensive Income (Loss). Ashland regularly assesses its servicing obligations and records them as assets or liabilities when appropriate. Ashland also monitors its obligation with regards to the limited guarantee and records the resulting guarantee liability when warranted. When applicable, Ashland discloses the amount of the accounts receivable that serves as over-collateralization as a restricted asset.

M-38

Foreign Accounts Receivable Sale Program

On October 19, 2023, Ashland entered, through an Ireland-based, wholly-owned, bankruptcy-remote consolidated special purpose entity (the "SPE"), into a three-year agreement with a group of entities (buyers) to sell certain accounts receivable, without recourse beyond the pledged receivables, of certain wholly-owned Ashland subsidiaries (Foreign Accounts Receivable Sale Program) primarily in Europe. Under the agreement, Ashland can transfer whole accounts receivable up to a limit established by the buyer, which is currently set at €125 million (a level 1 fair value measurement). Ashland's continuing involvement is limited to servicing the accounts receivable, including billing, collections and remittance of payments to the buyers as well as a limited guarantee on over-collateralization.

On September 24, 2026, Ashland entered into an Amendment associated with this current program. As part of this amendment the buyer's limit was maintained at €125 million through the termination date of the agreement on September 21, 2029.

Ashland determined that any accounts receivable transferred under this agreement are put presumptively beyond the reach of Ashland and its creditors, even in bankruptcy or other receivership. Ashland received true sale at law and non-consolidation opinions from independent qualified legal advisors in the jurisdiction of each originating subsidiary to support the legal isolation of these accounts receivable. Consequently, Ashland accounts for accounts receivable transferred to buyers as part of this agreement as sales.

The following table provides information related to the U.S. and Foreign Accounts Receivable Sale Programs as of September 30:

(In millions)

2026

2025

U.S. Accounts Receivable Sale Program

Buyer limit

$

68

$

59

Sales outstanding

68

59

Receivables transferred to SPE

86

75

Servicing and guarantee liability(a)

-

-

Foreign Accounts Receivable Sale Program

Buyer limit

$

107

$

103

Sales outstanding

107

103

Receivables transferred to SPE

143

142

Servicing and guarantee liability(a)

-

-

(a)
Zero denotes less than $1 million of activity.

The following table provides the impact of the U.S. and Foreign Accounts Receivable Sale Programs on the Statements of Consolidated Comprehensive Income (Loss) for the years ended September 30:

(In millions)

2026

2025

2024

U.S. Accounts Receivable Sale Program

Loss on sale

$

1

$

3

$

3

Foreign Accounts Receivable Sale Program

Loss on sale

$

2

$

5

$

3

The following table provides cash flow activity related to the U.S. and Foreign Accounts Receivable Sale Programs for the years ended September 30:

M-39

(In millions)

2026

2025

2024

U.S. Accounts Receivable Sale Program

Gross proceeds received

$

145

$

388

$

323

Cash collections

136

400

322

Net change in receivables sales volume

$

9

$

(12

)

$

1

Foreign Accounts Receivable Sale Program

Gross proceeds received

$

55

$

528

$

104

Cash collections

46

534

-

Net change in receivables sales volume

$

9

$

(6

)

$

104

Supply Chain Finance Program

During April 2024, Ashland authorized a financing program offered through JP Morgan and Taulia Alliance. Under this program, JP Morgan and its affiliates may purchase certain confirmed receivables directly from suppliers pursuant to the terms of a separate arrangement entered into between JPMorgan and Taulia Alliance and such suppliers. There were no changes to Ashland's standard payment terms with its suppliers in connection with this program. Ashland provides no guarantees to JP Morgan and Taulia Alliance under this program. The program was implemented during June 2025 and has been actively offered to suppliers. Participation in the program has not been significant. There were $20 million and less than $1 million of confirmed invoices under this program for the year ended September 30, 2026 and 2025, respectively. A rollforward of obligations confirmed and paid is presented below for the years ended September 30:

(In millions)

2026

2025

Confirmed obligations outstanding at beginning of period(a)

$

-

$

-

Invoices confirmed during the period(a)

20

-

Confirmed invoices paid during the period(a)

(16

)

-

Confirmed obligations outstanding at end of period(a)

$

4

$

-

(a)
Zero denotes less than $1 million of activity.

Other debt

At September 30, 2026 and 2025, Ashland held other debt totaling $81 million and $76 million, respectively, composed primarily of the 6.50% notes due 2029 and other notes.

Available borrowing capacity and liquidity

The borrowing capacity remaining under the 2026 Revolving Credit Facility was $496 million due to a reduction of $4 million for letters of credit outstanding at September 30, 2026. Ashland's total borrowing capacity at September 30, 2026 was $496 million.

Additionally, Ashland has no available liquidity under its current U.S. and Foreign Accounts Receivable Sale Programs.

Covenants related to current Ashland debt agreements

Ashland's debt contains usual and customary representations, warranties and affirmative and negative covenants, including financial covenants for leverage and interest coverage ratios, limitations on liens, additional subsidiary indebtedness, restrictions on subsidiary distributions, investments, mergers, sale of assets and

M-40

restricted payments and other customary limitations. As of September 30, 2026, Ashland was in compliance with all debt agreement covenant restrictions.

The maximum consolidated net leverage ratio permitted under the 2026 Credit Agreement is 4.0. The 2026 Credit Agreement defines the consolidated net leverage ratio as the ratio of consolidated indebtedness minus unrestricted cash and cash equivalents to consolidated EBITDA (Covenant Adjusted EBITDA) for any measurement period. In general, the 2026 Credit Agreement defines Covenant Adjusted EBITDA as net income (loss) plus consolidated interest charges, taxes, depreciation and amortization expense, fees and expenses related to capital market transactions and proposed or actual acquisitions and divestitures, restructuring and integration charges, certain environmental charges, non-cash stock and equity compensation expense, and any other nonrecurring expenses or losses that do not represent a cash item in such period or any future period; less any non-cash gains or other items increasing net income (loss). The computation of Covenant Adjusted EBITDA differs from the calculation of EBITDA and Adjusted EBITDA, which have been reconciled in the "Use of Non-GAAP Financial Measures" section. In general, consolidated indebtedness includes debt plus all purchase money indebtedness, banker's acceptances and bank guaranties, deferred purchase price of property or services, attributable indebtedness and guarantees. At September 30, 2026, Ashland's calculation of the consolidated net leverage ratio was 2.2.

The minimum required consolidated interest coverage ratio under the 2026 Credit Agreement is 3.0. The 2026 Credit Agreement defines the consolidated interest coverage ratio as the ratio of Covenant Adjusted EBITDA to consolidated interest charges for any measurement period. At September 30, 2026, Ashland's calculation of the consolidated interest coverage ratio was 7.0.

Any change in Covenant Adjusted EBITDA of $100 million would have an approximate 0.4x effect on the consolidated net leverage ratio and a 1.7x effect on the consolidated interest coverage ratio. Any change in consolidated indebtedness of $100 million would affect the consolidated net leverage ratio by approximately 0.3x.

Ashland credit ratings

Ashland's corporate credit rating was downgraded to BB by Standard & Poor's and to Ba2 by Moody's Investors Service during 2026. As of September 30, 2026, both Moody's Investor Services and Standard & Poor's outlook remained at stable. Subsequent changes to these ratings or outlook may have an effect on Ashland's borrowing rate or ability to access capital markets in the future.

Additional capital resources

Ashland cash projection

Ashland believes that cash flow from operations, availability under existing credit facilities and arrangements, current cash, cash equivalents, investment balances and the ability to obtain other financing, if necessary, will provide adequate cash funds for the Company's foreseeable working capital needs, capital expenditures at existing facilities, acquisitions, dividend payments and debt service obligations. The Company's cash requirements are subject to change as business conditions warrant and opportunities arise. The timing and

M-41

size of any new business ventures or acquisitions that the Company may complete may also impact its cash requirements.

Ashland expects the following material cash funding requirements from known contractual obligations at September 30, 2026:

Less than

More than

(In millions)

Total

1 year

1 year

Raw material and service contract purchase obligations(a)

$

47

$

21

$

26

Employee benefit obligations(b)

65

11

54

Operating lease obligations(c)

113

20

93

Interest payments(d)

439

53

386

Unrecognized tax benefits(e)

61

-

61

Total contractual obligations

$

725

$

105

$

620

Other commitments

Letters of credit(f)

$

52

$

52

$

-

(a)
Includes raw material and service contracts where minimal committed quantities and prices are fixed.
(b)
Includes estimated funding of Ashland's qualified U.S. and non-U.S. pension plans for 2027 as well as projected benefit payments through 2036 under Ashland's unfunded pension and other postretirement benefit plans. Excludes the benefit payments from the pension plan trust funds. See Note L of the Notes to Consolidated Financial Statements for additional information.
(c)
Includes leases for office buildings, transportation equipment, warehouses and storage facilities and other equipment. For further information, see Note J of the Notes to Consolidated Financial Statements.
(d)
Includes interest expense on both variable and fixed rate debt assuming no prepayments. Variable interest rates have been assumed to remain constant through the end of the term at rates that existed as of September 30, 2026.
(e)
Due to uncertainties in the timing of the effective settlement of tax positions with respect to taxing authorities, Ashland is unable to determine the timing of payments related to noncurrent unrecognized tax benefits, including interest and penalties. Therefore, these amounts were included in the "More than 1 year" column.
(f)
Ashland issues various types of letters of credit as part of its normal course of business.

Total Equity

Total equity was $1,848 million and $1,904 million at September 30, 2026 and 2025, respectively. During 2026, there was a decrease of $77 million for dividends paid during 2026. The decrease was partially offset by increases of $4 million for net income, $14 million for common shares issued under stock incentive plans, $2 million increase for unrealized gains on commodity hedges, and $1 million for deferred translation gains.

2023 Stock repurchase program

On June 28, 2023, Ashland's board of directors ("the Board") authorized a new evergreen $1 billion common share repurchase program ("2023 Stock Repurchase Program"). The new authorization terminated and replaced the 2022 Stock Repurchase Program, which had $200 million outstanding at the date of termination. As of September 30, 2026, $520 million remained available for repurchase under the 2023 Stock Repurchase Program. There was no share repurchase activity for the year ended September 30, 2026.

M-42

The following table provides the stock repurchase activity for years ended September 30:

(In millions, except per share amounts)

2025

2024

Number of shares repurchased

1.50

4.30

Weighted-average price per share(a)

$

64.90

$

88.70

Aggregate purchase price(a)

$

100

$

380

Program

2023 Stock Repurchase Program

2023 Stock Repurchase Program

(a)
Includes transactions costs.

Stockholder dividends

Ashland paid dividends per common share of $1.67, $1.64 and $1.58 during the years ended September 30, 2026, 2025 and 2024, respectively.

In May 2026, the Board announced a quarterly cash dividend of 42.0 cents per share to eligible stockholders at record, which represented an increase from the previous quarterly cash dividend of 41.5 cents per share. The dividend was paid in the third and fourth quarter of fiscal 2026.

In May 2025, the Board announced a quarterly cash dividend of 41.5 cents per share to eligible stockholders at record, which represented an increase from the previous quarterly cash dividend of 40.5 cents per share. The dividend was paid in the third and fourth quarter of fiscal 2025 and the first and second quarter of fiscal 2026.

In May 2024, the Board announced a quarterly cash dividend of 40.5 cents per share to eligible stockholders at record, which represented an increase from the previous quarterly cash dividend of 38.5 cents per share. The dividend was paid in the third and fourth quarter of fiscal 2024 and the first and second quarter of fiscal 2025.

In May 2023, the Board announced a quarterly cash dividend of 38.5 cents per share to eligible stockholders at record, which represented an increase from the previous quarterly cash dividend of 33.5 cents per share. The dividend was paid in the first and second quarter of fiscal 2024.

Capital expenditures

Capital expenditures were $88 million for 2026 and averaged $108 million during the last three years. Ashland expects capital expenditures over the next three years to average approximately $128 million per year. A summary of capital expenditures by reportable segment during the years ended September 30, are as follows:

(In millions)

2026

2025

2024

Life Sciences

$

31

$

49

$

61

Personal Care

9

7

11

Specialty Additives

42

34

61

Intermediates

4

3

2

Unallocated and other

2

5

2

Total capital expenditures

$

88

$

98

$

137

M-43

A summary of the capital employed in Ashland's current operations, which is calculated by adding equity to capital investment, as of September 30, is as follows:

(In millions)

2026

2025

Capital employed(a)

Life Sciences

$

1,303

$

1,377

Personal Care

645

703

Specialty Additives

842

904

Intermediates

99

97

(a)
Excludes the assets and liabilities classified within Unallocated and other which primarily includes debt and other long-term liabilities such as asbestos litigation reserves and pension. The net liability in Unallocated and other was $1,041 million and $1,175 million as of September 30, 2026 and 2025, respectively.

OFF-BALANCE SHEET ARRANGEMENTS

As part of its normal course of business, Ashland is a party to various financial guarantees and other commitments. These arrangements involve elements of performance and credit risk that are not included in the Consolidated Balance Sheets. The possibility that Ashland would have to make actual cash expenditures in connection with these obligations is largely dependent on the performance of the guaranteed party, or the occurrence of future events that Ashland is unable to predict. The fair value of these guarantees is not significant.

NEW ACCOUNTING PRONOUNCEMENTS

For a discussion and analysis of recently issued accounting pronouncements and their impact on Ashland, see Note A of the Notes to Consolidated Financial Statements.

CRITICAL ACCOUNTING ESTIMATES

The preparation of Ashland's Consolidated Financial Statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales and expenses, and the disclosures of contingent assets and liabilities. Significant items that are subject to such estimates and assumptions include, but are not limited to, environmental remediation, asbestos litigation, the accounting for goodwill and other indefinite-lived intangible assets and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ significantly from the estimates under different assumptions or conditions. Management has reviewed the estimates affecting these items with the Audit Committee of Ashland's Board of Directors.

Environmental remediation

Ashland is subject to various federal, state and local environmental laws and regulations that require environmental assessment or remediation efforts (collectively environmental remediation) at multiple locations. At September 30, 2026, such locations included 52 sites where Ashland has been identified as a potentially responsible party under Superfund or similar state laws, 106 current and former operating facilities and about 1,225 service station properties, of which 15 are being actively remediated.

Ashland's reserves for environmental remediation and related environmental litigation amounted to $222 million at September 30, 2026 compared to $226 million at September 30, 2025, of which $174 million at

M-44

September 30, 2026 and $179 million at September 30, 2025, were classified in other noncurrent liabilities on the Consolidated Balance Sheets. The remaining reserves were classified in accrued expenses and other liabilities on the Consolidated Balance Sheets.

The total reserves for environmental remediation reflect Ashland's estimates of the most likely costs that will be incurred over an extended period to remediate identified conditions for which the costs are reasonably estimable, without regard to any third-party recoveries. Engineering studies, historical experience and other factors are used to identify and evaluate remediation alternatives and their related costs in determining the estimated environmental remediation reserves. Ashland regularly adjusts its reserves as environmental remediation progresses and litigation develops. Ashland has estimated the value of its probable insurance recoveries associated with its environmental remediation reserves based on management's interpretations and estimates surrounding the available or applicable insurance coverage. At September 30, 2026 and 2025, Ashland's recorded receivable for these probable insurance recoveries was $13 million and $14 million, respectively, of which $11 million and $12 million, respectively, was classified in other noncurrent assets on the Consolidated Balance Sheets. The current portion is recorded within the accounts receivable, net caption of the Consolidated Balance Sheets.

During the years ended September 30, 2026, 2025 and 2024, Ashland recognized $37 million, $50 million and $54 million of expense, respectively, for certain environmental liabilities related to normal ongoing remediation cost estimate updates for sites, which is consistent with Ashland's historical environmental accounting policy. See Note M of the Notes to Consolidated Financial Statements for additional information.

Environmental remediation reserves are subject to uncertainties that affect Ashland's ability to estimate its share of the costs. Such uncertainties involve the nature and extent of contamination at each site and the extent of required cleanup efforts under existing environmental regulations. Although it is not possible to predict with certainty the ultimate costs of environmental remediation, Ashland currently estimates that the upper end of the reasonably possible range of future costs for identified sites could be as high as approximately $470 million (current reserve of $222 million). The largest environmental remediation reserve for any site is 22% of the total environmental remediation reserves as of September 30, 2026.

Asbestos litigation

Ashland and Hercules have liabilities from claims alleging personal injury caused by exposure to asbestos. To assist in developing and annually updating independent reserve estimates for future asbestos claims and related costs, Ashland has retained third party actuarial experts Gnarus Advisors, LLC ("Gnarus"). The methodology used by Gnarus to project future asbestos costs is based largely on recent experience, including claim-filing and settlement rates, disease mix, open claims and litigation defense. The claim experience of Ashland and Hercules are separately compared to the results of previously conducted third party epidemiological studies estimating the number of people likely to develop asbestos-related diseases. Those studies were undertaken in connection with national analyses of the population expected to have been exposed to asbestos. Using that information, Gnarus estimates a range of the number of future claims that may be filed, as well as the related costs that may be incurred in resolving those claims. Changes in asbestos litigation reserves and receivables are recorded on an after-tax basis within the discontinued operations caption in the

M-45

Statements of Consolidated Comprehensive Income (Loss). See Note M of the Notes to Consolidated Financial Statements for additional information.

Ashland asbestos-related litigation

The claims alleging personal injury caused by exposure to asbestos asserted against Ashland result primarily from indemnification obligations undertaken in 1990 in connection with the sale of Riley, a former subsidiary. The amount and timing of settlements and number of open claims can fluctuate from period to period.

Ashland asbestos-related liability

From the range of estimates, Ashland records the amount it believes to be the best estimate of future payments for litigation defense and claim settlement costs. Ashland reviews this estimate and related assumptions quarterly and annually updates the results of a non-inflated, non-discounted approximate 35-year model developed with the assistance of Gnarus.

During the most recent update completed during 2026, it was determined that the liability for Ashland asbestos-related claims should be increased by $31 million. Total reserves for asbestos claims were $257 million at September 30, 2026 compared to $258 million at September 30, 2025.

Ashland asbestos-related receivables

Ashland has insurance coverage for certain litigation defense and claim settlement costs incurred in connection with its asbestos claims, and coverage-in-place agreements exist with the insurance companies that provide substantially all of the coverage that will be accessed.

For the Ashland asbestos-related obligations, Ashland has estimated the value of probable insurance recoveries associated with its asbestos litigation reserves based on management's interpretations and estimates surrounding the available or applicable insurance coverage, including an assumption that all solvent insurance carriers remain solvent. Substantially all of the estimated receivables from insurance companies are expected to be due from domestic insurers, all of which are solvent.

At September 30, 2026, Ashland's receivable for recoveries of litigation defense and claim settlement costs from insurers (excluding the Hercules receivable for asbestos claims) amounted to $102 million. Receivables from insurers amounted to $95 million at September 30, 2025. During 2026, the annual update of the model used for purposes of valuing the asbestos litigation reserves and its impact on valuation of future recoveries from insurers, was completed. This model update resulted in a $15 million increase in the receivable for probable insurance recoveries.

Hercules asbestos-related litigation

Hercules has liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims typically arise from alleged exposure to asbestos fibers from resin encapsulated pipe and tank products which were sold by one of Hercules' former subsidiaries to a limited industrial market. The amount and timing of settlements and number of open claims can fluctuate from period to period.

M-46

Hercules asbestos-related liability

From the range of estimates, Ashland records the amount it believes to be the best estimate of future payments for litigation defense and claim settlement costs. Ashland reviews this estimate and related assumptions quarterly and annually updates the results of a non-inflated, non-discounted approximate 35-year model developed with the assistance of Gnarus. As a result of the most recent annual update of this estimate completed during 2026, it was determined that the liability for Hercules asbestos-related claims should be increased by $17 million. Total reserves for asbestos claims were $174 million at September 30, 2026 compared to $177 million at September 30, 2025.

Hercules asbestos-related receivables

For the Hercules asbestos-related obligations, certain reimbursement obligations pursuant to coverage-in-place agreements with insurance carriers exist. As a result, any increases in the asbestos litigation reserves have been partially offset by probable insurance recoveries. Ashland has estimated the value of probable insurance recoveries associated with its asbestos litigation reserves based on management's interpretations and estimates surrounding the available or applicable insurance coverage, including an assumption that all solvent insurance carriers remain solvent. The estimated receivable consists exclusively of solvent domestic insurers.

As of September 30, 2026 and 2025, the receivables from insurers amounted to $52 million and $48 million, respectively. During 2026, the annual update of the model used for purposes of valuing the asbestos litigation reserves and its impact on valuation of future recoveries from insurers was completed. This model update resulted in a $7 million increase in the receivable for probable insurance recoveries.

Asbestos litigation cost projection

Projecting future asbestos costs is subject to numerous variables that are difficult to predict. In addition to the uncertainties surrounding the number of claims that might be received, other variables include the type and severity of the disease alleged by each claimant and the related costs incurred in resolving those claims, mortality rates, dismissal rates, uncertainties surrounding the litigation process from jurisdiction to jurisdiction and from case to case. Furthermore, any predictions with respect to these variables are subject to even greater uncertainty as the projection period lengthens. In light of these inherent uncertainties, Ashland believes that the asbestos litigation reserves for Ashland and Hercules represent the best estimate within a range of possible outcomes. As a part of the process to develop these estimates of future asbestos costs, a range of long-term cost models was developed. These models are based on national studies that predict the number of people likely to develop asbestos-related diseases and are heavily influenced by assumptions regarding long-term inflation rates for indemnity payments and legal defense costs, as well as other variables mentioned previously. Ashland has currently estimated in various models ranging from approximately 35-year periods that it is reasonably possible that total future litigation defense and claim settlement costs on an inflated and undiscounted basis could range as high as approximately $375 million for the Ashland asbestos-related litigation (current reserve of $257 million) and approximately $256 million for the Hercules asbestos-related litigation (current reserve of $174 million), depending on the combination of assumptions selected in the various models. While the timeframe used in Ashland's models for projecting asbestos liabilities generally decreases over time based on the expected lifetime of the liabilities, these models have been consistently applied within all periods

M-47

presented. If actual experience is worse than projected, relative to the number of claims filed, the severity of alleged disease associated with those claims or costs incurred to resolve those claims, or actuarial refinement or improvements to the assumptions used within these models are initiated, Ashland may need to further increase the estimates of the costs associated with asbestos claims and these increases could be material over time.

Accounting for goodwill and other indefinite-lived intangible assets

Ashland accounts for goodwill and other indefinite-lived intangible assets acquired in a business combination in conformity with current accounting guidance which does not allow for goodwill and indefinite-lived intangible assets to be amortized.

Goodwill

Ashland reviews goodwill for impairment annually as of July 1 or when events and circumstances indicate an impairment may have occurred. Ashland tests goodwill for impairment by comparing the estimated fair value of its reporting units to the related carrying value. If the fair value of the reporting unit is lower than its carrying amount, goodwill is written down for the amount by which the carrying amount exceeds fair value. However, the loss recognized cannot exceed the carrying amount of goodwill. Reporting units are defined as either operating segments or one level below the operating segments for which discrete financial information is available and reviewed by management. Ashland determined that its reporting units are Life Sciences, Personal Care, Specialty Additives and Intermediates, which is consistent with prior years.

Ashland makes various estimates and assumptions in determining the estimated fair value of each reporting unit using a combination of discounted cash flow models and valuations based on earnings multiples for guideline public companies in each reporting unit's industry peer group. Discounted cash flow models are reliant on various assumptions, including projected business results, long-term growth factors and weighted-average cost of capital. Management judgment is involved in estimating these variables, and they include uncertainties since they are forecasting future events. Ashland performs sensitivity analyses by using a range of inputs to confirm the reasonableness of the terminal growth rate and weighted-average cost of capital estimates. Additionally, Ashland compares the indicated equity value to Ashland's market capitalization and evaluates the resulting implied control premium/discount to determine if the estimated enterprise value is reasonable.

On July 1, 2026, the date of our annual goodwill impairment assessment, Ashland evaluated each reporting unit using a quantitative approach and concluded that the reporting unit fair values for all reporting units exceeded their carrying values. No impairment existed as of that date and no subsequent indicators of impairment have been identified for the year ended September 30, 2026. For further information, see Note G of the Notes to Consolidated Financial Statements.

During the third quarter of fiscal 2025, Ashland experienced a continued decline in the market price of its common stock. Ashland also experienced slowing growth due to weakening macroeconomic environment that dampened consumer sentiment and demand globally which resulted in lower growth and lower margins for the Life Sciences and Specialty Additives reporting units than what was previously forecasted. These factors led

M-48

Ashland to determine that triggering events occurred, and a quantitative goodwill impairment assessment was performed during the third quarter of fiscal 2025.

Following the completion of this quantitative analysis, Ashland concluded that the fair value of Personal Care reporting unit exceeded its carrying value by more than 100%. The Intermediates reporting unit has no associated goodwill. The carrying value of the Life Sciences and the Specialty Additives reporting units exceeded their fair value, resulting in non-cash goodwill impairment charges of $375 million and $331 million, respectively, for a total goodwill impairment charge of $706 million, which was recorded within the goodwill impairment caption of the Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2025.

On July 1, 2025, the date of prior year's annual goodwill impairment assessment, Ashland evaluated each reporting unit using a qualitative approach focusing on any additional changes in market conditions, performances versus forecast and strategic initiatives. Particular attention was given to forward looking macroeconomic trends and forecasts, recent financial results, earnings multiples for guideline public companies in each reporting unit's industry peer group and sensitivity analysis for each reporting units discounted cash flow model. There was no additional impairment identified as part of the July 1, 2025 annual goodwill impairment assessment. For further information, see Note G of the Notes to Consolidated Financial Statements.

As of September 30, 2026, as a result the factors and other factors discussed above and the limited cushion (or headroom as commonly referred) for the Specialty Additives reporting unit after the 2025 impairment, goodwill is more susceptible to impairment risk. The below table provides a sensitivity analysis for the Specialty Additives reporting unit remaining goodwill, utilizing reasonably possible changes in the assumptions for the shorter term and terminal growth rate and the weighted-average cost of capital, to demonstrate the potential impacts to the estimated fair value. The below table provides, in isolation, the estimated fair value impacts related to a 25-basis point increase to the weighted-average cost of capital or a 25-basis point decrease to the terminal growth rate, neither of which would result in an impairment charge to the Specialty Additives reporting unit for the year ended September 30, 2026.

Approximate Percent Change in Estimated Fair Value

+25 bps

-25 bps

Weighted-Average Cost of Capital

Terminal Growth Rate

Specialty Additives

-2.8%

-1.5%

Assumptions inherent in the valuation methodologies include estimates of future projected business results (principally sales and EBITDA), terminal growth rates, and the weighted-average cost of capital. Significant assumptions utilized in the annual goodwill impairment assessment included the weighted-average cost of capital, ranging between 11.75% and 13.00% in 2026 (12.50% and 13.75% in 2025), and terminal growth rates, ranging between 2.0% and 4.0% in both 2026 and 2025 depending on the reporting unit. For further information, see Note G of the Notes to Consolidated Financial Statements.

Other indefinite-lived intangible assets

Other indefinite-lived intangible assets include certain trademarks and trade names. Ashland reviews these intangible assets for possible impairment annually as of July 1 or whenever events or changes in circumstances

M-49

indicate that carrying amounts may not be recoverable. If the carrying value of an individual indefinite-lived intangible asset exceeds its fair value, the asset is written down to its fair value and the amount of the write down is the impairment charge. Similar to its annual assessment for goodwill, Ashland performs a quantitative test for impairment.

Ashland tests these assets using a "relief-from-royalty" valuation method to determine the fair value. Assumptions inherent in the valuation methodologies include, but are not limited to, future projected business results, growth rates, the weighted-average cost of capital for a market participant, and royalty rates. In conjunction with the July 1 annual assessment of indefinite-lived intangible assets, Ashland's quantitative approach models did not indicate any impairment, as each indefinite-lived intangible assets fair value exceeded its carrying values.

Ashland's assessment of an impairment on any of these assets classified currently as having indefinite lives, including goodwill, could change in future periods if significant events happen and/or circumstances change that affect the previously mentioned assumptions. Assumptions inherent in the valuation methodologies include, but are not limited to, such estimates as future projected business results, growth rates, the weighted-average cost of capital for a market participant, and royalty rates. For further information, see Note G of the Notes to Consolidated Financial Statements.

Income taxes

Ashland is subject to income taxes in the United States and numerous foreign jurisdictions. Judgment in the forecasting of taxable income using historical and projected future operating results is required in determining Ashland's provision for income taxes and the related assets and liabilities. The provision for income taxes includes income taxes paid, currently payable or receivable, and deferred taxes. Under U.S. GAAP, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Deferred tax assets are also recognized for the estimated future effects of tax loss and credit carryforwards. The effect on deferred taxes of changes in tax rates is recognized in the period in which the enactment date occurs. Valuation allowances are established when necessary on a jurisdictional basis to reduce deferred tax assets to the amounts expected to be realized. Deferred taxes are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested. In the event that the actual outcome of future tax consequences differs from Ashland's estimates and assumptions due to changes or future events such as tax legislation, geographic mix of earnings, completion of tax audits or earnings repatriation plans, the resulting change to the provision for income taxes could have a material effect on the Statements of Consolidated Comprehensive Income (Loss) and Consolidated Balance Sheets.

The recoverability of deferred tax assets and the recognition and measurement of uncertain tax positions are subject to various assumptions and judgment by Ashland. If actual results differ from the estimates made by Ashland in establishing or maintaining valuation allowances against deferred tax assets, the resulting change in the valuation allowance would generally impact earnings or other comprehensive income depending on the nature of the respective deferred tax asset. Additionally, the positions taken with regard to tax contingencies

M-50

may be subject to audit and review by tax authorities, which may result in future taxes, interest and penalties. Positive and negative evidence is considered in determining the need for a valuation allowance against deferred tax assets, which includes such evidence as historical earnings, projected future earnings, tax planning strategies and expected timing of reversal of existing temporary differences.

In determining the recoverability of deferred tax assets, Ashland gives consideration to all available positive and negative evidence including reversals of deferred tax liabilities (other than those with an indefinite reversal period), projected future taxable income, tax planning strategies and recent financial operations. Ashland attaches the most weight to historical earnings due to their verifiable nature. In evaluating the objective evidence that historical results provide, Ashland considers three years of cumulative income or loss. In addition, Ashland has reflected increases and decreases in our valuation allowance based on the overall weight of positive versus negative evidence on a jurisdiction by jurisdiction basis.

EFFECTS OF INFLATION AND CHANGING PRICES

Ashland's Consolidated Financial Statements are prepared on the historical cost method of accounting in accordance with U.S. GAAP and, as a result, do not reflect changes in the purchasing power of the U.S. dollar. Monetary assets (such as cash and cash equivalents and accounts receivable) lose purchasing power as a result of inflation, while monetary liabilities (such as accounts payable and indebtedness) result in a gain, because they can be settled with dollars of diminished purchasing power. As of September 30, 2026, Ashland's monetary liabilities exceed its monetary assets, reducing its exposure to the loss of purchasing power associated with monetary assets during the period of inflation. Inflation has fluctuated from 2024 to 2026. See Item 1A - Risk Factors for additional information.

Certain of the industries in which Ashland operates are capital-intensive, and replacement costs for its plant and equipment generally would substantially exceed their historical costs. Accordingly, depreciation and amortization expense would be greater if it were based on current replacement costs. However, because replacement facilities would reflect technological improvements and changes in business strategies, such facilities would be expected to be more productive than existing facilities, mitigating at least part of the increased expense.

OUTLOOK

Ashland is issuing the following guidance for fiscal 2027, reflecting its current expectations for market conditions, business performance and continued execution of its strategic priorities.

Full-year fiscal 2027 guidance

•
Sales: $1,905 million to $1,975 million, reflecting growth of approximately two to six percent over the prior year;
•
Adjusted EBITDA: $405 million to $435 million;
•
Ongoing Free Cash Flow Conversion: greater than 40 percent of Adjusted EBITDA, reflecting a modest increase in inventory and capital expenditures of up to approximately $140 million.

M-51

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements including, without limitation, statements made under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations" ("MD&A"), within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its Annual Report to Stockholders, quarterly reports and other filings with the Securities and Exchange Commission (SEC), news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance and financial condition, as well as the economy and other future events or circumstances.

The risks and uncertainties we face which may cause our actual results to differ materially from the results expressed, projected, or implied in these forward-looking statements include, but are not limited to: Ashland's aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, and any unexpected costs and liabilities associated with such acquisitions; goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland's products; risks inherent in operating a global business, including tariffs and other trade policies, and geopolitical instability and armed conflict; economic downturns and disruptions in the financial markets; Ashland's substantial Indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward pressures on prices and margins; the ability to attract and retain key employees, including across foreign jurisdictions where employment and business and cultural practices may differ, and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland's information technology systems and networks, malicious cyberattacks, the inadvertent or accidental disclosure or loss of proprietary or sensitive information, and cyber risks related to Ashland's external service providers and other third parties; risks related to Ashland use of artificial intelligence, including the potential for flawed or unreliable outputs, and the complexities and uncertainties in the legal and regulatory landscapes; Ashland's ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; and changes in taxation or adverse tax rulings. These risks and uncertainties also include, but are not limited to, the risk factors set forth in Item 1A. "Risk

M-52

Factors" to this Annual Report on Form 10-K, elsewhere in this Annual Report on Form 10-K, and in our other periodic reports filed with the SEC. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update publicly any forward-looking statements made in this Annual Report on Form 10-K whether as a result of new information, future events or otherwise. Information on Ashland's website is not incorporated into or a part of this Annual Report on Form 10-K.

Ashland Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 20, 2026 at 17:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]